

# IOF Regionals *Australia* 11

2<sup>nd</sup> Asia-Pacific Osteoporosis and Bone Meeting  
ANZBMS Annual Scientific Meeting **WITH JSBMR**

**4-8 SEPTEMBER 2011**

**GOLD COAST CONVENTION AND EXHIBITION CENTRE • AUSTRALIA**



## PROGRAMME

[www.anzbms-iof.org](http://www.anzbms-iof.org)



**ANZBMS**



**International  
Osteoporosis  
Foundation**

**SPRINGER MATTER**

# TABLE OF CONTENTS

*As of July 8, 2011 • Subject to change*

Meeting Organization	4
Message from the Meeting Chairs	5
International Osteoporosis Foundation (IOF)	6
Australian and New Zealand Bone and Mineral Society (ANZBMS)	8
Japanese Society for Bone and Mineral Research (JSBMR)	9
Programme Summary	10
Programme-at-a-Glance	14
Speakers	16
Sponsors & Exhibitors	27
Trade Directory	28
Venue Information	32
About Gold Coast, Queensland	36
Travel Information	37
Practical Information	38
Registration Information	40
Social Events	43
Scientific Sessions Information	45
IOF Young Investigator Award	46
ANZBMS Past Award Recipients	47
JSBMR Travel Award Recipients	48
Final Programme	50
Poster Listing	62
Plenary Lecture Abstracts	
Oral Communication Abstracts	
Poster Presentation Abstracts	
Satellite Symposia Abstracts	
Venue Map	

# MEETING ORGANIZATION

As of July 8, 2011 • Subject to change

## SCIENTIFIC PROGRAMME COMMITTEE

Emma Duncan ANZBMS **Co-Chair**

Cyrus Cooper IOF **Co-Chair**

Paul Anderson ANZBMS

Suthorn Bavonratanavech IOF

Siok Bee Chionh IOF

Simon Cool ANZBMS

Gustavo Duque ANZBMS

Mark Forwood ANZBMS

Seiji Fukumoto JSBMR

Hiroshi Hagino IOF

Tai-Pang Ip IOF

Graeme Jones ANZBMS

John A. Kanis IOF

Edith Lau IOF

Sarath Lekamwasam IOF

Ambrish Mithal IOF

Keiichi Ozono JSBMR

Allison Pettit ANZBMS

René Rizzoli IOF

Ego Seeman IOF AND ANZBMS

Gethin Thomas ANZBMS

Hyun Koo Yoon IOF

## LOCAL ORGANIZING COMMITTEE

Mark Forwood ANZBMS **Chair**

Emma Duncan ANZBMS

Edith Lau IOF

Julie Li-Yu IOF

Rebecca Mason ANZBMS

Andy Wu ANZBMS

## HOST REVIEW PANEL

Matthew Gillespie ANZBMS

Rebecca Mason ANZBMS

Patrice McKenney IOF

Judy Stenmark IOF

## CONFERENCE SECRETARIAT

### ASN Events

PO Box 200

Balnarring, Victoria 3926, Australia

**T** +61 3 5983 2400 ■ **F** +61 3 5983 2223

*mp@asnevents.net.au* ■ *www.asnevents.net.au*

## MEETING VENUE

### Gold Coast Convention and Exhibition Centre

Corner Gold Coast Highway & TE Peters Drive

Broadbeach, Queensland ■ 4218, Australia

**T** +61 7 5504 4000 **F** +61 7 5504 4001

*www.gccec.com.au*

## MEETING WEBSITE

[www.anzbms-iof.org](http://www.anzbms-iof.org)

# MESSAGE FROM THE MEETING CHAIRS

The Organising Committees extend their warmest welcome to all participants attending this combined Meeting involving the International Osteoporosis Federation (IOF), the Australian and New Zealand Bone and Mineral Society (ANZBMS) and the Japanese Society for Bone and Mineral Research (JSBMR). We hope you will find this to be a truly exciting Meeting presenting both the breadth and depth of clinical and basic research in bone.

Our scientific programme includes invited plenary presentations and seminars, Meet-the-Expert sessions, basic and clinical abstract presentations, young investigator awards, and interactive poster sessions. Our speakers have been drawn from Australia, China, India, Japan, New Zealand, Singapore, UK, and the USA. Over 300 abstracts have been submitted from over 30 countries – so we will have a truly international meeting while maintaining a strong regional representation and focus on the Asia-Pacific Region. This is particularly timely, after the IOF Asian Audit in 2009 revealed that by 2050 more than 50% of all osteoporotic fractures worldwide will occur in Asia.

There will, of course, be many opportunities to network and discuss science and medicine. Our Local Organising Committee has organised a spectacular opening function, including a welcome from the Traditional Owners of the land, student and young investigator functions, a special session for women with careers in skeletal science, our Gala Dinner-Dance, and of course the annual fun run/walk finishing with breakfast on one of the renowned Gold Coast beaches.

We hope you enjoy the Meeting.

Yours sincerely,



EMMA  
DUNCAN



CYRUS  
COOPER



MARK  
FORWOOD



KEIICHI  
OZONO



# INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF)

The International Osteoporosis Foundation (IOF) is the only worldwide organization dedicated to the prevention, diagnosis and treatment of osteoporosis. It is a Swiss not-for-profit Foundation acting as an umbrella organization bringing together all stakeholders; including, scientists, physicians, patient and medical societies as well as corporate partners interested in osteoporosis, osteoarthritis and bone health.

IOF has three membership committees including the Committee of National Societies (CNS) representing 200 member societies in 93 countries or regions, the Committee of Scientific Advisors (CSA) represented by 125 thought leaders from around the world and the Committee of Corporate Advisors (CCA), comprised of 33 companies interested in bone health.

IOF organizes its operations from its headquarters office in Nyon, Switzerland, as well as regional offices in Singapore, Dubai and Buenos Aires. It mobilizes the global osteoporosis movement on World Osteoporosis Day October 20, every year. Part of the IOF's mission is to support and enhance the work of its member societies which is reflected in many programmes and projects, including the IOF World Wide Conference of Osteoporosis Patient Societies, held every two years.

IOF also organizes annual Regional Scientific Meetings, often in partnership with other organizations. These include the IOF Regionals in the Asia-Pacific, Latin America and Middle-East & Africa regions, and the IOF-ECCEO European Congress on Osteoporosis and Osteoarthritis. Additionally, IOF holds training courses around the world including the flagship course, the IOF Advanced Training Course on Osteoporosis in Geneva, Switzerland. Beginning in 2012, IOF will offer Joint ISCD-IOF Osteoporosis Diagnostic and Management Courses on a worldwide basis.

IOF's scientific publication portfolio includes the journals *Osteoporosis International*, *Archives of Osteoporosis*, and *Progress in Osteoporosis*. A free access online review journal is available at [www.iofbonehealth.org/pio](http://www.iofbonehealth.org/pio).

## IOF REGIONALIZATION PROGRAMME

IOF has increasingly focussed on regionalization, a long-term plan for the development of a strong regional structure based on collaboration among the member associations at the regional level. The programme is helping IOF to better serve specific local needs and will contribute to the dynamic growth of IOF and the strengthening of osteoporosis associations worldwide.

At present three regional offices service the needs of IOF members. The IOF Asia-Pacific Regional Office opened in Singapore in August 2010 and the IOF Middle-East and Africa office opened in Dubai, United Arab Emirates in 2011. The IOF Latin American Regional Office, located in Buenos Aires, Argentina, has been active for almost a decade, carrying out training courses, public awareness activities and health professional education throughout the region.



**International Osteoporosis  
Foundation**

rue Juste-Olivier, 9 ■ 1260 Nyon ■ Switzerland  
T +41 22 994 0100 ■ F +41 22 994 0101  
[info@iofbonehealth.org](mailto:info@iofbonehealth.org) ■ [www.iofbonehealth.org](http://www.iofbonehealth.org)

## MEMBERS OF THE IOF BOARD

- Jonathan Adachi CANADA
- Silvano Adami ITALY
- John Bilezikian USA
- Juliet Compston UK
- Steven Cummings USA
- Bess Dawson-Hughes USA *General Secretary*
- Harry K. Genant USA
- John A. Kanis UK *President*
- Edith Lau HONG KONG, CHINA
- Rubem Lederman BRAZIL
- Uri Liberman ISRAEL
- Basel Masri JORDAN
- Paul D. Miller USA
- Hajime Orimo JAPAN
- Socrates Papapoulos THE NETHERLANDS
- Jean-Yves Reginster BELGIUM
- Gregorio Riera-Espinoza VENEZUELA
- René Rizzoli SWITZERLAND *Treasurer*
- Ego Seeman AUSTRALIA
- Ethel S. Siris USA
- José Zanchetta ARGENTINA

### *Ex-officio Members*

#### **Elected chairs of CNS, CSA, CCA:**

- Cyrus Cooper UK CSA
- José Zanchetta ARGENTINA CNS
- Laurence Alliot FRANCE CCA

#### **Vice Chairs of the CNS, CSA and CCA:**

- René Rizzoli SWITZERLAND CSA
- Norma Piggott SWITZERLAND CCA
- Jean-Yves Reginster BELGIUM CNS
- Famida Jiwa CANADA Chair, CNS Patient Societies Subcommittee

#### **Editors of *Calcified Tissue International*:**

- Roberto Civitelli USA
- Stuart Ralston UK



An essential element of the IOF regionalization programme is the establishment of regular regional scientific meetings, the 'IOF Regionals'. These meetings help to raise standards of osteoporosis education in the regions and to provide an international high-profile forum for regional research. They also give many clinicians the opportunity to attend high quality international clinical meetings 'close to home'. In this respect, the 1<sup>st</sup> Asia-Pacific Osteoporosis Meeting, held in December 2010 in Singapore, was a great success, attracting more than 1000 attendees and 200 abstracts from around the world and the region.

Another important element is the election of Regional Advisory Councils (RAC) from among the member societies in the regions.

## REGIONAL EPIDEMIOLOGICAL AUDITS

The 'Asian Audit – Epidemiology, costs and burden of osteoporosis in Asia 2009', published by IOF in cooperation with 14 member Asian national societies in 2009, was the first of a series of landmark publications which serve to gain media attention and energize research and policy work in the regions. The Asian Audit was followed by a regional audit for Eastern Europe & Central Asia, published in December 2010. IOF is currently developing a Middle-Eastern and African Regional Audit which will be published in October 2011 and a Latin American Regional Audit for 2012.

## THE ASIA-PACIFIC REGION

IOF counts thirty-one member patient, medical and scientific societies in the Asia-Pacific region. With the launch of the Asia-Pacific Regional Office in August 2010 in Singapore, IOF appointed Ms. Rhonda Ng [rng@iofbonehealth.org](mailto:rng@iofbonehealth.org) as IOF Asia-Pacific Coordinator.

### Regional Advisory Council for Asia-Pacific Region *Elected December 2010*

- Ambrish Mithal **Chair** INDIA
- Suthorn Bavonratanavech THAILAND
- Siok Bee Chionh SINGAPORE
- Hiroshi Hagino JAPAN
- Tai-Pang Ip HONG KONG, SAR
- Sarath Lekamwasam SRI LANKA
- Philip Sambrook AUSTRALIA

### Ex-officio Regional Advisory Council

- Edith Lau HONG KONG, SAR
- Hajime Orimo JAPAN
- Ego Seeman AUSTRALIA

## IOF MEMBER SOCIETIES IN THE ASIA-PACIFIC REGION *As of July 2011*

- Australian and New Zealand Bone and Mineral Society (ANZBMS)
- Osteoporosis Australia (OA)
- Osteoporosis Committee of China Gerontological Society
- China Health Promotion Foundation (CHPF)
- China Osteoporosis Foundation (COF)
- Hong Kong Osteoporosis Foundation (HKOF)
- Osteoporosis Society of Hong Kong (OSHK)
- Asian Pacific Osteoporosis Foundation (APOF)
- Taiwanese Osteoporosis Association (TOA)
- Indian Rheumatology Association (IRA)
- Arthritis Foundation of Indian Trust (AFI)
- The Indian Society for Bone and Mineral Research (ISBMR)
- Osteoporosis Society of India (OSI)
- Indonesian Osteoporosis Society - Perhimpunan Osteoporosis Indonesia (PEROSI)
- Indonesian Healthy Bone Foundation (PERWATUSI)
- The Japanese Society for Bone and Mineral Research (JSBMR)
- Japan Osteoporosis Society (JOS)
- Japan Osteoporosis Foundation (JOF)
- The Korean Society of Osteoporosis (KSO)
- The Korean Society of Bone Metabolism
- Malaysian Osteoporosis Society (MSO)
- Osteoporosis Awareness Society of Kuala Lumpur (OASKL)
- Osteoporosis New Zealand
- Osteoporosis Society of Pakistan (OSP)
- Gujranwala Osteoporosis Patient Society (GOPS)
- Osteoporosis Society of the Philippines Foundation Inc. (OSPFI)
- Osteoporosis Society (Singapore) (OSS)
- Endocrine and Metabolic Society of Singapore (EMSS)
- Osteoporosis Society of Sri Lanka
- Thai Osteoporosis Foundation (TOPF)
- Vietnam Rheumatology Association (VRA)

# AUSTRALIAN AND NEW ZEALAND BONE AND MINERAL SOCIETY (ANZBMS)

Australian and New Zealand Bone and Mineral Society is a professional medical/scientific society established in 1989 to bring together clinical and experimental scientists and physicians actively involved in the study of bone and mineral metabolism in Australia and New Zealand. ANZBMS is the premier Australasian society in the field of bone and mineral metabolism which promotes excellence in bone and mineral research, fosters the integration of clinical and basic science, and facilitates the translation of our science to health care and clinical practice.



145 Macquarie Street • Sydney, NSW 2000  
Australia  
**T** 61 2 9256 5405 **F** +61 2 9251 8174  
[anzbms@racp.edu.au](mailto:anzbms@racp.edu.au)  
[www.anzbms.org.au](http://www.anzbms.org.au)

## ANZBMS COUNCIL MEMBERS 2011

<b>President</b> Rebecca Mason	<b>Councillors</b> Nigel Gilchrist Gethin Thomas Natalie Sims Markus Seibel
<b>President Elect</b> Matthew Gillespie	<b>Past President</b> Philip Sambrook
<b>Honorary Secretary</b> Gerald Atkins	
<b>Honorary Treasurer</b> Roger Price	

**ANZBMS Annual Scientific Meeting 2012**

**September 2-5, 2012**

**Pan Pacific, Perth, Western Australia**

[www.anzbms.org.au](http://www.anzbms.org.au)

## PAST & PRESENT COUNCILLORS 1990-2009

YEAR	PRESIDENT	VICE PRESIDENT	SECRETARY	TREASURER	COUNCILLORS
<b>1990 (Steering Group)</b>	T. J. Martin		M. Hooper		A. Need, R. Prince, J. Eisman, I. Reid, K. Ibbertson, D. Fraser, P. Sambrook, E. Seeman
<b>1991-93 (Inaugural Council)</b>	T. J. Martin		M. Hooper	M. Hooper	J. Eisman, A. Goulding, D. Perry-Keen, J. Wark, A. Need, N. Kent
<b>1993-95</b>	J. Eisman	I. Reid	N. Kent	J. Wark	P. Sambrook, A. Need, R. Prince, D. Perry-Keene, E. Seeman
<b>1995-97</b>	I. Reid	N. Kent	J. Moseley	P. Ebeling	P. Sambrook, A. Need, R. Prince, D. Perry-Keene
<b>1997-99</b>	N. Kent	P. Ebeling	J. Moseley	P. Ebeling	R. Prince, I. Reid, M. Hooper, H. Morris, M. Forwood
<b>1999-01</b>	P. Ebeling	M. Hooper	J. Cornish	M. Forwood	J. Moseley, H. Morris, E. Mackie, M. Zheng
<b>2001-03</b>	M. Hooper	E. Seeman	J. Cornish	M. Forwood	R. Mason, R. Price, G. Nicholson, D. Findlay
<b>2003-05</b>	E. Seeman	J. Cornish	D. Findlay	M. Forwood	R. Mason, R. Price, G. Nicholson, P. Sambrook
<b>2005-07</b>	J. Cornish	P. Sambrook	D. Findlay	R. Price	G. Nicholson, R. Mason, M. Gillespie, P. Nash
<b>2007-09</b>	P. Sambrook	R. Mason	M. Gillespie	R. Price	P. Nash, T. Cundy, N. Fazzalari, M. Kotowicz



# JAPANESE SOCIETY FOR BONE AND MINERAL RESEARCH (JSBMR)

## PURPOSE

The Japanese Society for Bone and Mineral Research (JSBMR) is a professional medical/scientific society established to promote the study of problems pertaining to bones and other musculoskeletal tissues and mineral metabolism through annual scientific meetings and official Journal (Journal of Bone Mineral Metabolism).

## ORIGIN

The Society was founded at first as a research cooperative meeting in 1967, and developed to the JSBMR in 1982. The first annual meeting was held by Professor Norimasa Hosoya, Tokyo University, in 1983.

## MEMBERSHIP

The JSBMR membership comprises physicians, dentists, basic scientists, and clinical investigators in bone and mineral metabolism and related fields. Current membership numbers reach approximately 2,400, which is classified as follows:

- Regular members: Individuals who support the goals of the JSBMR. Annual fee is 9,000 yen.
- Student members: Individuals who are the student of the postgraduate course and the University. Annual fee is 4,000 yen.
- Honorary members: Individuals who satisfy requirements to be set forth separately do not need to pay a membership fee.
- Supporting members: Individuals and corporations who support the goals of the JSBMR. Annual fee is 100,000 yen (per unit).

## OFFICIAL JOURNAL

### Journal of Bone and Mineral Metabolism

Impact Factor: 1.894 (2010)

JBMM Submission Site

<http://www.springer.com/medicine/internal/journal/774>

JBMM Editorial Secretary

[jbmm@ac-square.co.jp](mailto:jbmm@ac-square.co.jp)



Academic Square Co., LTD 2-348-302,  
Ryogae-machi Fushimi-ku Kyoto, 612-8082  
Japan

**T** +81-75-468-8772 **F** +81-75-468-8773

[jbmm@ac-square.co.jp](mailto:jbmm@ac-square.co.jp)

[jbmm.umin.jp/eng/index.html](http://jbmm.umin.jp/eng/index.html)

## JSBMR COUNCIL

### President

Toshiyuki Yoneda, D.D.S., Ph.D.

### Vice president

Toshio Matsumoto, M.D., Ph.D.

### Directors

Eiji Itoi, M.D., Ph.D.

Masako Ito, M.D., Ph.D.

Shigeaki Kato, D.Agr., Ph.D.

Toshihisa Komori, M.D., Ph.D.

Toshitsugu Sugimoto, M.D., Ph.D.

Satoshi Soen, M.D., Ph.D.

Hiroshi Hagino, M.D., Ph.D.

Hideki Mizunuma, M.D., Ph.D.

Akira Yamaguchi, D.D.S., Ph.D.

### Inspectors

Hiroaki Ohta, M.D., Ph.D.

Yoshiki Seino, M.D., Ph.D.

### Secretariat

JBMM Editorial Secretary

[jbmm@ac-square.co.jp](mailto:jbmm@ac-square.co.jp)

JBMM Submission Site

<http://www.springer.com/medicine/internal/journal/774>

# PROGRAMME SUMMARY

## SUNDAY SEPTEMBER 4, 2011

16:00-16:15 ARENA 1B  
**Opening Ceremony**

16:15-17:45 ARENA 1B  
**OSTEOPOROSIS IN OCEANIA AND THE ASIA-PACIFIC REGION**

*CO-CHAIRS* John A. Kanis & Toshio Matsumoto

- **Secular trends in fracture incidence: Why are fractures increasing in Asia but falling in the west?** *C. Cooper*
- **Strategies to overcome epidemic of Vitamin D deficiency in Asia** *A. Mithal*
- **Strategies for fracture prevention in Asia - Where do we go from here?** *E. Lau*

17:45-19:30 EXHIBITION HALL  
**Welcome Reception & Opening of Exhibition**

## MONDAY SEPTEMBER 5, 2011

07:30-08:30 ARENA 1B  
**Breakfast Meeting presented by Novartis Pharmaceuticals**  
**Efficacy and Safety of Long-term Treatment with Zolendric Acid 5 mg** *E. F. Eriksen*

07:30-08:30  
**Meet-the-Expert Sessions**

- **Cancer and Bone** *T. Yoneda* ROOM 4
- **Economic evaluation of osteoporosis**  
*J. A. Kanis* ROOM 5  
*The Meeting acknowledges the sponsorship of Servier*
- **Vitamin D, common sense and the Goldilocks principle** *N. Binkley* ROOM 6
- **Genetics in the dissection of bone biology**  
*M. Warman* ROOM 7

08:30-09:50 ARENA 1B

### OSTEOPOROSIS IN MEN

*CO-CHAIRS* Peter Ebeling & Rachel Davey

- **Men, osteoporosis and body composition** *E. Orwoll*
- **Osteoprotective actions of sex hormones mediate their nuclear receptors in bone cells**  
*S. Kato*
- **Androgens are critical to neuropeptide Y mediated control of bone formation** *A. Zengin*

09:50-10:20 EXHIBITION HALL

### Morning Tea

10:20-12:00 ARENA 1B

### RHEUMATOLOGY AND BONE

*CO-CHAIRS* Stuart Ralston & Matt Brown

- **Osteoimmunology** *H. Takayanagi*
- **Inflammation and bone resorption in rheumatoid arthritis** *S. Goldring*
- **Inflammation and bone formation in ankylosing spondylitis** *G. Thomas*

10:20-12:00 ROOMS 5 & 6

### IOF Young Investigator Session and Awards

*CO-CHAIRS* Cyrus Cooper & Ambrish Mithal

12:00-12:30 EXHIBITION HALL

### Lunch

*The Meeting acknowledges the sponsorship of Servier*

12:30-13:30 ARENA 1B

### Satellite Symposium

13:30-14:30 EXHIBITION HALL

**Poster Session** Odd numbers

14:30-16:00 ARENA 1B

### Clinical Invited Abstracts - Therapeutics

*CO-CHAIRS* Toshio Matsumoto & Philip Sambrook

14:30-16:10 ROOMS 5 & 6

**WORKSHOP ON BONE REGENERATION** presented with the Australian and New Zealand Orthopaedic Research Society

**CO-CHAIRS** Aaron Schindeler & Christopher Vidal

- Lowering the efficacious dose of BMP-2 using heparan glycosaminoglycans *S. Cool*
- Adipose stem cells and craniofacial regeneration *Y. Lin*
- A basis for building bone: Novel biomaterials for new bone growth *H. Zreiqat*
- The contribution of soft tissue osteoprogenitors to spinal fusion *J. Bobyen*

16:00-16:30 EXHIBITION HALL

Afternoon Tea

16:30-17:30 ARENA 1B

**FRACTURE RISK ALGORITHMS: SOOTHSAYING OR SCIENCE?**

**CO-CHAIRS** Neil Binkley & Julie Pasco

- Getting to Grips with FRAX®: How it really works *J. A. Kanis*
- Effect of co-morbidities on fracture risk: Findings from the GLOW study *E. Dennison*
- Absolute fracture risk-based clinical threshold for Intervention: A decision curve analysis *N. Nguyen*

16:30-17:30 ROOMS 5 & 6

**Basic Abstracts - Connective Tissue**

**CO-CHAIRS** Simon Cool & TBC

17:30-18:30 ARENA 1B

**Satellite Symposium presented by MSD**

18:30-19:30 ROOMS 5 & 6

**Zumba Fitness Class**

**TUESDAY SEPTEMBER 6, 2011**

07:30-08:30 ARENA 1B

**Women in Bone Function**

**CHAIR** Rebecca Mason

**Does a successful career in science assume a choice between a research career and being a 'primary carer'?**

*Ms Leneen Forde AC, Chancellor of Griffith University*

07:30-08:30

**Meet-the-Expert Sessions**

- The role of the Vitamin D receptor in bone health *S. Kato* ROOM 4
- Osteoporosis: When to measure, what to measure, whom to treat and with what? *S. Ralston* ROOM 5
- Rheumatoid arthritis and bone *S. Tanaka* ROOM 6
- Vertebral fracture: Definition, clinical impact and epidemiology considerations *C. Cooper* ROOM 7

*The Meeting acknowledges the sponsorship of Eli Lilly*

08:30-09:50 ARENA 1B

**THE EFFECTS OF AGEING**

**CO-CHAIRS** Eric Orwoll & Gustavo Duque

- Sarcopenia, aging and sarco-osteoporosis *N. Binkley*
- Sarcopaenia and vitamin D *D. Scott*
- Prevalence of sarcopenia in older women: The Geelong Osteoporosis Study *J. Pasco*
- Role of Tmem119 in the muscle ossification signaling *K. Tanaka*

09:50-10:15 EXHIBITION HALL

Morning Tea

*The Meeting acknowledges the sponsorship of Eli Lilly*

10:15-12:00 ARENA 1B

**NON-CANONICAL BONE**

**CO-CHAIRS** Alvin Ng & Emma Duncan

- Non canonical bone: Bone fat brain *P. Baldock*
- Bones and salt: The renin-angiotensin-aldosterone axis in bone *C. Nowson*
- LRP5, serotonin and bone *M. Warman*
- The role of osteocalcin in glucocorticoid-induced metabolic dysfunction *T. Brennan-Speranza*

10:15-12:00 ROOMS 5 & 6

**MALIGNANCY AND BONE**

**CO-CHAIRS** David Thomas & Toshio Matsumoto

- Pathophysiology of bone disease in multiple myeloma *A. Zannettino*
- Mechanisms and prevention for cancer chemotherapy-induced bone defects *C. Xian*
- Bone pain associated with cancer metastasis to bone *T. Yoneda*
- Treatment with interleukin 6 receptor antibodies inhibits prostate cancer growth in a murine model of bone metastasis *D. Basel*

12:00-12:30 EXHIBITION HALL  
**Lunch**

12:35-13:35 ARENA 1B  
**Satellite Symposium presented by Amgen in association with GlaxoSmithKline Australia**

13:35-14:30 EXHIBITION HALL  
**Poster Session** Even numbers

14:30-16:10 ARENA 1B  
**CLINICAL MANAGEMENT OF OSTEOPOROSIS I**  
*CO-CHAIRS* Edith Lau & Rory Clifton-Bligh

- **To BMD or not to BMD?** J. A. Kanis
- **The role of fracture liaison services in the management of patients with osteoporosis** M. Seibel
- **Incidence and prevention of second hip fracture in Japan** H. Hagino
- **Timing of adverse outcomes following osteoporotic fractures in elderly women and men: Implication for long term management** D. Bliuc

14:30-16:00 ROOMS 5 & 6  
**Basic Abstracts**  
*CO-CHAIRS* Nao Takahashi & Natalie Sims

16:00-16:30 EXHIBITION HALL  
**Afternoon Tea**

16:30-17:30 ARENA 1B  
**ANZBMS Annual General Meeting**

17:30-18:30 ARENA 1B  
**New Investigator Session**  
*CO-CHAIRS* Andy Wu & Tara Brennan-Spinoza  
*CO-CHAIRS* Ashika Chhana & Desa Walsh

18:30-19:30 ARENA 1B  
**Satellite Symposium presented by Novartis Pharmaceuticals**

19:30-22:00 KURRAWA SURF LIFE SAVING CLUB  
**Young Investigator BBQ Buffet**

## WEDNESDAY SEPTEMBER 7, 2011

07:30-08:30 ARENA 1B  
**Student - Mentor Breakfast**  
**Building a Career in Skeletal Research: From Foundations to Penthouse Suite**  
*A. Pettit and M. Gillespie*

07:30-08:30  
**Meet-the-Expert Sessions**

- **Bone and cartilage pathophysiology in osteoarthritis: Therapeutic implications** S. Goldring ROOM 4
- **Sex steroids and bone in men: What to measure, what to treat?** E. Orwoll ROOM 5
- **How does adipose tissue affect the skeleton? Laboratory studies** J. Cornish ROOM 6
- **Vitamin D derivatives** T. Matsumoto ROOM 7

08:30-09:50 ARENA 1B  
**PAGET'S DISEASE**  
*CO-CHAIRS* Neil Binkley & Ian Reid

- **The epidemiology of Paget's disease** T. Cundy
- **Genetics of Paget's disease of bone** S. Ralston
- **Paget's disease of bone-associated Sequestosome 1/p62 mutant proteins increase RANKL-induced AP-1 signalling and affect cellular co-localisation with key signalling intermediates Ajuba and TRAF6** S. Rea

09:50-10:15 EXHIBITION HALL  
**Morning Tea**

10:15-12:00 ARENA 1B  
**BIOMECHANICS AND BONE MEASUREMENT**  
*CO-CHAIRS* Satoshi Mori & Belinda Beck

- **Why bones fail: Structure and mechanics** M. Forwood
- **Quantifying the material composition and structure of bone non-invasively** E. Seeman
- **Osteocytes and calcium: A little bit of give and take** D. Findlay
- **Analysis of oxidative stress and antioxidant enzymes in mechanical stress response** D. Morikawa

10:15-12:00 ROOMS 5 & 6  
**SKELETAL DYSPLASIAS**  
*CO-CHAIRS* Keiichi Ozono & Emma Duncan

- **Skeletal dysplasias: A new approach** A. Zankl
- **Hypophosphataemia and FGF23** S. Fukumoto
- **Mouse models for skeletal dysplasias** M. Warman
- **Variable osteogenesis imperfecta phenotype resulting from a founder FKBP10 mutation in Samoa** T. Cundy

12:00-13:00 EXHIBITION HALL  
**Lunch**

12:00-13:00 EXHIBITION HALL  
**New Investigator Oral Poster Session**

13:00-14:00 ARENA 1B  
**Satellite Symposium**

14:00-15:50 ARENA 1B  
**THERAPEUTICS IN OSTEOPOROSIS: CONTROVERSIES**

**CO-CHAIRS** John Eisman & Graeme Jones

- **Bisphosphonates: The good, the bad and the ugly** P. Ebeling
- **Fracture healing -Mechanical and histological changes with bisphosphonate treatment** S. Mori
- **Atypical subtrochanteric and diaphyseal femoral fractures - What we know and what we don't** A. Ng
- **Adverse cardiovascular effects of calcium supplements may not persist after discontinuation of supplements: 5-year follow up of the Auckland Calcium Study** L. Wigg
- **Does calcium supplementation with and without vitamin D increase cardiovascular risk? A clinico-Bayesian interpretation** T. Thach

14:00-15:40 ROOMS 5 & 6  
**OSTEOCLASTS**

**CO-CHAIRS** Hiroshi Takayanagi & Gerald Atkins

- **Quiescent osteoclast precursors** N. Takahashi
- **Epigenetic regulation of osteoclast differentiation** S. Tanaka
- **Osteoblastic support of osteoclasts: the role of gp130 signalling** N. Sims
- **An osteoclast-derived coupling factor** S. Takeshita

15:45-16:15 EXHIBITION HALL  
**Afternoon Tea**

16:15-17:55 ARENA 1B  
**ANZBMS Young Investigator Award Session**  
**CO-CHAIRS** Stuart Ralston & Steven Goldring

16:15-17:45 ROOMS 5 & 6  
**Clinical Abstracts - Bone Nutrition**  
**CO-CHAIRS** Paul Anderson & TBC

16:30-18:00 ROOM 7  
**IOF Regional Advisory Council Meeting** invitation only

19:30-23:00 ARENA 2  
**Gala Dinner** ticketed function

## THURSDAY SEPTEMBER 8, 2011

07:00-08:15 KURRAWA SURF LIFE SAVING CLUB  
**Beach Breakfast**

09:00-10:45 ARENA 1B

### PAEDIATRIC BONE DISEASE

**CO-CHAIRS** Ambrish Mithal & TBC

- **Measuring a growing skeleton, and the effect of ethnicity on bone and body composition** C. Cowell
- **Nutrition and children's bone** T. Winzenberg
- **Osteoporosis and osteopetrosis in the young** K. Ozono
- **Growth from birth to adulthood and bone mineral density data from the New Delhi Birth Cohort** N. Tandon
- **Longitudinal change of bone geometry in the mid femur of growing children** P. Bridge

09:00-10:45 ROOM 5

### Final Oral Abstracts

**CO-CHAIRS** Geoff Nicholson & TBC

10:45-11:15 FOYERS A & B  
**Morning Tea**

11:15-12:45 ARENA 1B

### CLINICAL OSTEOPOROSIS MANAGEMENT II

**CO-CHAIRS** Stuart Ralston & John A. Kanis

- **New strategies for treatment of osteoporosis** T. Matsumoto
- **Osteoporosis management and mortality** J. Center
- **Osteoporosis: The future** J. Eisman

12:45-13:15 ARENA 1B  
**Closing Remarks**

# PROGRAMME-AT-A-GLANCE

	SUN SEPT 4	MON SEPT 5	TUES SEPT 6	WED SEPT 7	THURS SEPT 8
07.00					Beach Breakfast
08.00		Morning Tea	Women in Bone Function	Student Mentor Breakfast	
		Meet-the-Expert (x4)	Meet-the-Expert (x4)	Meet-the-Expert (x4)	
09.00		Plenary	Plenary	Plenary	Plenary (x2)
10.00		Morning Tea	Morning Tea	Morning Tea	Morning Tea
11.00		Plenary	Plenary (x2)	Plenary (x2)	Plenary
		IOF Young Investigator Awards			
12.00		Lunch	Lunch	Lunch	Closing Remarks
		Satellite Symposium	Satellite Symposium	Satellite Symposium	
13.00		Exhibition	Exhibition	Exhibition	
		Poster Session	Poster Session		
14.00	Registration Desk Opens				
15.00		Plenary	Plenary (x2)	Plenary (x2)	
		Workshop			
16.00	Official Opening	Afternoon Tea	Afternoon Tea	Afternoon Tea	
17.00	Opening Plenary	Plenary (x2)	ANZBMS Annual General Meeting	Plenary	
		Satellite Symposium	Plenary	ANZBMS Young Investigator	
18.00	Exhibition	Welcome Reception	Satellite Symposium		
19.00		Zumba Fitness Class	Satellite Symposium		
20.00			Young Investigator BBQ Buffet		
21.00				Gala Dinner	
22.00					

As of July 8, 2011 • Subject to change



# IOF Regionals DUBAI '11

1<sup>st</sup> Middle-East & Africa Osteoporosis Meeting

**19-22 OCTOBER 2011**

**INTERCONTINENTAL FESTIVAL CITY • DUBAI, UAE**



# SPEAKERS


---



## **Paul Baldock**

Dr. Paul Baldock received his PhD in 2001 at the University of Adelaide in the Department of Human Physiology. He investigated the response of cancellous bone to ovarian hormone deficiency under the supervision of Professor Howard Morris. Subsequently, he moved to the Garvan Institute where he is RD Wright Fellow and Head of the Bone Neurobiology Group in the Neuroscience Program.

---



## **Dr. Neil Binkley**

Earned his medical degree from the University of Wisconsin Medical School and subsequently received his training in Internal Medicine at the Marshfield Clinic. After several years in private practice, he returned to the University of Wisconsin and completed a Geriatrics fellowship. He is an Associate Professor in the Divisions of Geriatrics and Endocrinology at the University of Wisconsin where he is also Director of the UW Osteoporosis Clinical Center and Research Program and Associate Director of the UW Institute on Aging. He is past President of the International Society for Clinical Densitometry. His current research involves evaluation of approaches to optimize evaluation of vitamin D status, exploring racial/ethnic differences in response to vitamin D supplementation, evaluation of functional assessment in older adults and the importance of sarcopenia in fracture risk.

---



## **Jackie Center**

A/Prof Jackie Center is a Senior Research Officer in the Osteoporosis and Bone Biology Research Program at the Garvan Institute of Medical Research, Senior Staff Specialist Endocrinologist at St Vincent's Hospital and Ass. Professor of Medicine at University of New South Wales. She began her endocrine training in Sydney and completed it at the Harvard Hospitals group, Boston, followed by a Masters of Epidemiology at the Harvard School of Public Health. She returned to the Garvan Institute in Sydney to complete her PhD. The major focus of her research has been the epidemiology of osteoporosis and fracture and their outcomes. She is a main investigator on the Dubbo Osteoporosis Epidemiology Study and has pioneered research into the consequence of fracture including the high risk of refracture and associated premature mortality. She has co-authored over 60 articles in international journals.

---



## **Simon Cool**

Simon Cool received his PhD from the University of Queensland, Australia and then took a Faculty position at the School of Biomedical Sciences, University of Queensland, Australia in 1997. In 2003 he joined the Institute of Molecular and Cell Biology, A\*STAR, Singapore as a Principal Investigator with an Adjunct Position in the Dept. of Orthopaedic Surgery, National University of Singapore and in 2008 he moved to the Institute of Medical Biology, A\*STAR, Singapore. He is also an Adjunct Professor at Wake Forest Institute for Regenerative Medicine (WFIRM), North Carolina, USA. His research is focused on developing novel glycosaminoglycan biomolecules that enhance orthopaedic repair and control mesenchymal stem cell fates. He has filed numerous patent applications and has published broadly. He is Editor of several major journals.

---



### **Cyrus Cooper**

Cyrus Cooper is Professor of Rheumatology and Director of the MRC Lifecourse Epidemiology Unit at the University of Southampton, and Chair of Musculoskeletal Science at the University of Oxford. After completing his residency and a Fellowship at the Mayo Clinic, USA, he became Senior Lecturer in Rheumatology and MRC Senior Clinical Scientist. He was promoted to the foundation Chair in Rheumatology at the University of Southampton in 1997 while continuing as an MRC Senior Clinical Scientist at the MRC Environmental Epidemiology Unit. In 2003, he was appointed Director of the MRC Epidemiology Resource Centre, University of Southampton (now the MRC Lifecourse Epidemiology Unit). Professor Cooper is past-President of the Bone Research Society of Great Britain and Chair of the IOF Committee of Scientific Advisors. He has served as Chair of the NOS and has worked on numerous committees and working groups. He is Chair of the MRC Population Health Sciences Research Network and Ass. Director of Research at the University of Southampton Medical School. He has published extensively and pioneered clinical studies on the developmental origins of peak bone mass.

---

### **Jillian Cornish**

Professor Cornish leads the Cell and Molecular Bone Biology Research Group in the Department of Medicine, University of Auckland, New Zealand and she also holds a visiting professorship with University of Oxford, UK. The group investigates the mechanism of action of a number of peptides and lipids that are anabolic to bone and for which they hold international patents. Professor Cornish is on the boards of the International Bone and Mineral Society, International Bone Morphometry Society and is a past-president of Australian and New Zealand Bone and Mineral Society

---



### **Christopher Cowell**

Chris Cowell is Director of the Kids Research Institute at The Children's Hospital at Westmead. He has been Director of Clinical Research at the Hospital since 2005, a part-time position created to help advocate and develop clinical research and its infrastructure. A Professor of the University of Sydney, Prof Cowell trained as a paediatric endocrinologist in Toronto and Sydney and has extensive clinical and research experience in diabetes, growth, obesity-related metabolic syndrome and disorders of bone metabolism. His major research interests are the prevention of metabolic complications of obesity in teenagers and the effects of disease states on bone mass and bone geometry.

---



### **Tim Cundy**

Tim Cundy is a Professor of Medicine at the University of Auckland, New Zealand. He has published extensively on Paget's disease of bone and other metabolic and genetic bone diseases.

---



### **Peter Ebeling**

Professor Ebeling is Chair, NorthWest Academic Centre, University of Melbourne and Head of Endocrinology, at Western Hospital, in Victoria. He has served on the Editorial Board of Journal of Bone and Mineral Research since 2001 and is currently an Associate Editor. He also serves on the Editor Board of Osteoporosis International, is Medical Director of Osteoporosis Australia, Councilor-Elect of ASBMR and a past-President of the Australian and New Zealand Bone and Mineral Society.



### **John Eisman**

John Eisman AO (MB BS, PhD, FRACP) is a Professor of Medicine (Conjoint) of the University of New South Wales, a Staff Endocrinologist at St. Vincent's Hospital in Sydney and Director of the Osteoporosis & Bone Biology at the Garvan Institute of Medical Research. He initiated and has run the Bone and Calcium clinic at St Vincent's Hospital and the Dubbo Osteoporosis Epidemiology Study since their inception more than 20 years ago. He is a co-founder and past-President of the Australia and New Zealand Bone & Mineral Society. He chaired the inaugural Australian National Health Priority Action Council's National Arthritis and Musculoskeletal Conditions Advisory Group and co-chaired its successor, the Australian Better Arthritis and Osteoporosis Expert Advisory Committee. He is co-chair of the NSW Health Agency for Clinical Innovation in Musculoskeletal conditions. The focus of his research is the epidemiology and genetics of osteoporosis, encompassing population, family and twin studies as well as molecular and cellular mechanisms for gene effects.



### **David Findlay**

David Findlay is Professor of Orthopaedic Research in the Discipline of Orthopaedics and Trauma at The University of Adelaide. His undergraduate and postgraduate studies were at The University of Melbourne, followed by postdoctoral work at the National Institutes of Health, Maryland, USA. He has worked in bone and joint research for over 30 years, focussing on the mechanisms of pathological bone loss, both systemic, such as in osteoporosis, or focal, such as in bone cancer or around orthopaedic implants.



### **Mark Forwood**

Mark Forwood is Professor and Foundation Chair of Anatomy at Griffith University at the Gold Coast. His research expertise includes functional adaptation of the skeleton, skeletal maturation and orthopaedic biomechanics. He has contributed to understanding the significance of fatigue microdamage to bone quality and fragility. In the 90's, his NHMRC postdoctoral fellowship with David Burr and Charles Turner, Indiana University, established fluid flow in vivo as a mechanism in mechanotransduction, and pioneered studies revealing the relationship between bisphosphonate treatment and microdamage burden. Recent work has focussed on the pathophysiology of stress fractures and optimising the tissue quality of bone allografts.



### **Seiji Fukumoto**

Dr. Fukumoto received his MD degree in 1982 and PhD degree in 1990 from the University of Tokyo. He consequently spent a couple of years in the laboratory headed by Prof. T.J. Martin in Melbourne, Australia. His areas of interest include homeostatic control and derangements of mineral metabolism, and pathogenesis and treatment of metabolic bone diseases.

---





### **Steven Goldring**

Steven R. Goldring, MD is the St. Giles Chair and Chief Scientific Officer at Hospital for Special Surgery and Professor of Medicine at Weill Cornell Medical College in New York City. He previously was a Professor of Medicine at Harvard Medical School and Chief of Rheumatology at Beth Israel Deaconess Medical Center, Boston, Massachusetts. He is the past President and Secretary-Treasurer of the American Society of Bone and Mineral Research and prior Chairman of the Research Committee of the National Arthritis Foundation. He previously served as the Chairman of the Orthopaedics and Musculoskeletal Study Section at the National Institutes of Health and Co-Chairman of the Keystone Conference on the Pathogenesis of Rheumatoid Arthritis.

---



### **Hiroshi Hagino**

Dr Hagino is Professor and head of the Rehabilitation Division and School of Health Science at Tottori University Faculty of Medicine in Yonago, Tottori, Japan. In 1982, he joined the Japanese National Board of Medicine followed by membership on the Japanese Board of Orthopedic Surgery in 1989 and the Japanese Board of Rehabilitation Medicine in 2002. He is also a member of the Japanese Orthopedic Association, the Japanese Association of Rehabilitation Medicine, the Japanese Society for Bone and Mineral Research, and the American Society for Bone and Mineral Research.

---



### **John A Kanis**

Prof. John A. Kanis is Emeritus Professor in Human Metabolism, and Director, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. He is the President of the International Osteoporosis Foundation. Prof. Kanis' contributions to research include cell biology, histomorphometry of bone, assessment and treatment of bone disorders, guideline development, health technology assessment, epidemiology and health economics. He holds several honorary positions and is WHO Advisor on Osteoporosis. Prof. Kanis is the Editor of 'Osteoporosis International'. His current major interest is in the development of risk assessment algorithms and the formulation of practice guidelines in many regions of the world.

---



### **Shigeaki Kato**

Professor Kato was awarded his PhD in 1988 from the University of Tokyo, assistant professor – to associate professor in the Tokyo University of Agriculture from 1988 to 1996. In 1987, he worked with Prof. Pierre Chambon (Strasbourg). Then, Prof. Kato became independent at IMCB, the University of Tokyo from 1996, full professor at 1998. He was awarded by 13 organizations including Fuller Albright award from American Society of Bone and Mineral Research (ASBMR) in 1998, and the 2000 international prize from Austrian SBMR. A major interest is to understand functions of nuclear receptors in transcriptional and epigenomic controls, and their roles in bone.

---



### **Edith Lau**

Dr Edith Lau is currently the Director for the Asia Pacific region of Center for Clinical and Basic Research (CCBR)-Synarc. She is also clinical consultant for the Hong Kong Orthopaedic and Osteoporosis Center for treatment and Research. Dr Edith Lau obtained her Doctorate of Medicine Degree from the Chinese University of Hong Kong in 1991. She was inaugurated as a Professor in Community Medicine in 2001 and set up the Hong Kong Jockey Club Center for Osteoporosis Care and Control, the first center of its kind in Asia. In 2004, Dr Lau founded the Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research. Dr Lau is a board member of the IOF and founding president of the Asian Pacific Osteoporosis Foundation and the Hong Kong Osteoporosis Foundation.

---



### **Yunfeng Lin**

Yunfeng Lin, D.D.S., M.D., Ph.D., is Professor of State Key Laboratory of Oral Diseases, Sichuan University. He serves as the Vice-director of State Key Laboratory of Oral Diseases and Assistant Dean of West China School of Stomatology. He received his Ph.D. from Sichuan University in 2006. Dr. Lin's research focus is on adipose stem cells differentiation and craniofacial regeneration, such as bone, cartilage, tooth, fat et al. He has published over 60 papers, reviews and book chapters, and made several seminal contributions to the stem cells fields. Dr. Lin's awards and honors include New Century Excellent Talents of Chinese Ministry of Education, National Excellent Doctoral Dissertation of China, Scopus' Future Star of Science award in China.

---



### **Toshio Matsumoto**

Toshio Matsumoto, M.D. is professor and chair at the Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Medical Sciences, Tokushima, Japan. He has published over 260 original articles in peer-reviewed journals. He has served as a Councilor of the ASBMR (2000-2002), a Board member of the IBMS (1995-2005), JSBMR (2005-present), Japan Endocrine Society (2003-present), and an Advisory Committee member of the Cancer-Associated Bone Society (2005-present). His major scientific interests are: regulation of osteoblast differentiation, pathophysiology and treatment of cancer-induced bone diseases, and translational research and clinical development of drugs for osteoporosis treatment.

---



### **Ambrish Mithal**

Dr Ambrish Mithal is presently the Chair and Head of Endocrinology and Diabetes division at Medanta, the Medicity where he has established one of India's premier diabetes and endocrinology centres. He was the first DM in Endocrinology from the All India Institute of Medical Sciences (1987), and subsequently served on the faculty at Sanjay Gandhi PGI, Lucknow (1988-1998), Dept. of Endocrinology. He has been Senior Consultant at Apollo Hospital, New Delhi, where he established DNB (endocrinology) training program. Dr Mithal is Past President of the Endocrine Society of India and the Chair of the Bone and Joint Decade, India. He is the founder and currently Chief Advisor to the ISBMR (India). He chairs the IOF Nutrition Working Group and has been elected Chair of IOF's Asia-Pacific Advisory Council.

---



### **Satoshi Mori**

Professor, Seirei Hamamatsu General Hospital. Education history: 1975-1981, Medical School: Kanazawa University, School of Medicine; 1992, Degree: Ph.D. (University of the Ryukyus). Research and Faculty appointments include: 1985-1987, Clinical assistant, Department of Orthopedic Surgery, University of the Ryukyus, Japan; 1987 –1989, Research Associate, Radiobiology Div. University of Utah (USA); 1989-1990, Research Associate, Department of Anatomy, West Virginia University (USA); 1990-1991, Research Associate, Department of Anatomy, Indiana University (USA); 1991-1994, Clinical assistant, Department of Orthopedic Surgery, University of the Ryukyus, Japan; 1994-2007, Associate professor, Department of Orthopedic Surgery, Kagawa University; 2007-present, Chief of Bone and Joint Surgery, Seirei Hamamatsu General Hospital.

---





### **Alvin Ng**

Dr. Alvin Ng received his medical degree from the National University of Singapore and attained his MRCP (Internal Medicine) in 2003 and Specialist Accreditation in Endocrinology in 2007. In 2008, he trained with the Osteoporosis and Bone Metabolism research group at Mayo Clinic, Rochester, Minnesota. His current research focuses on the epidemiology of osteoporotic fractures, relationship between obesity and osteoporosis, and myeloma bone disease. He was appointed to the American Society of Bone and Mineral Research Task Force on Atypical Femoral Fractures in 2009. He currently serves as a Consultant in the Department of Endocrinology, Singapore General Hospital and holds adjunct teaching positions at the National University of Singapore and Duke-NUS Graduate Medical School.

---



### **Caryl Nowson**

Dr. Caryl Nowson holds the chair of Professor of Nutrition and Ageing, School of Exercise and Nutrition Sciences and team leader of Food, Lifestyle and Health group within the Centre for Physical Activity and Nutrition Research at Deakin University. Prof. Nowson is an Accredited Practising Dietitian. Her research has focused on two major diseases of ageing, specifically nutrition related to hypertension, bone health and more recently vitamin D. Professor Nowson has published widely, demonstrating the effectiveness for dietary interventions, particularly reduction of dietary sodium and increasing dietary potassium. In 2009 she was awarded the Nutrition Society of Australia Medal. She is a member of the scientific advisory committee of Osteoporosis Australia and was the founding chairperson of the Australian division of World Action group on Salt and Health in 2005.

---



### **Eric Orwoll**

Dr. Orwoll is Professor of Medicine and Attending Physician in the Bone and Mineral Section of the Division of Endocrinology, Diabetes, and Clinical Nutrition. An internationally recognized expert in the area of bone biology and metabolic bone disease, he has extensive experience in basic, clinical, and epidemiological research. Areas of research include the epidemiology, etiology and therapy of osteoporosis in men, the evaluation of new diagnostics and therapeutics, effects of sex steroids on skeletal biology, and skeletal genetics. He is the author of more than 250 publications and is an experienced leader in academic medicine, with extensive responsibility for clinical and translational research planning and management. He is Associate Vice-President for Research at OHSU, Associate Dean for Clinical Research in the School of Medicine, and the Director of the Oregon Clinical and Translational Research Institute.

---



### **Keiichi Ozono**

Keiichi Ozono obtained his MD and PhD at Osaka University Medical School. From 1989 to 1991 he was a research associate at the Dept. of Paediatrics and Cell Biology of Baylor College of Medicine, in Houston. In 1994 he became a department head of the Dept. of Environmental Medicine of the Osaka Medical Center and Research Institute for Maternal and Child Health. He has been a professor at the Department of Paediatrics at Osaka University, Graduate School of Medicine since 2002. He is a member of the ASBMR, IBMS, American Endocrine Society, Asia Pacific Paediatric Endocrine Society, Japanese Society of Bone and Mineral Metabolism, Japanese Society of Endocrinology, Japanese Society of Pediatrics, and Japanese Society for Pediatric Endocrinology. He is an Editor-in-Chief of Clinical Pediatric Endocrinology as well as an Editor of Journal of Bone and Mineral Metabolism.

---



### **Stuart Ralston**

Stuart Ralston is Arthritis Research UK Professor of Rheumatology at the University of Edinburgh and honorary consultant rheumatologist with NHS Lothian, based in Edinburgh. He graduated in Medicine from Glasgow University and developed an interest in bone disease during postgraduate training. He was appointed as a Wellcome Senior Research Fellow at Edinburgh University in 1989 and moved to the University of Aberdeen where he was appointed Senior Lecturer in Medicine. He was awarded a Personal chair in Medicine and Bone Metabolism 1996 at Aberdeen where he remained until he took up his present position. Professor Ralston has researched several aspects of bone disease and has a particular interest in the genetic basis of osteoporosis and Paget's disease. He is a fellow of the Royal College of Physicians of Edinburgh, Academy of Medical Sciences and Royal Society of Edinburgh.

---



### **David Scott**

David Scott's research has investigated the influence of lifestyle behaviours on physical health status in specialised populations. His previous work, utilising data from the Tasmanian Older Adult Cohort study, has provided important evidence on the role of physical activity, diet, medication use and sun exposure in the progression of sarcopaenia. He is currently employed by the Institute for Health and Social Science Research at CQUniversity and is investigating the associations of these lifestyle behaviours and others with poor physical health in individuals with serious mental illness.

---



### **Ego Seeman**

Professor of Medicine, Endocrinologist, Dept Medicine at Austin Health, University of Melbourne. Worked in the study of metabolic bone disease 30 years; 300 publications, H index 54; Past President Australian & New Zealand Bone Mineral Society; Editor Progress in Osteoporosis, Assoc. Editor Osteoporos Int, BoneKey; Board member IOF. Awards - 2002 Fred C. Bartter Award American Society of Bone Mineral Research; 2008 Austin Hospital Medical Research Foundation Distinguished Scientist Award; 2009 International Osteoporosis Foundation Medal of Achievement for Outstanding Investigation in Osteoporosis Research.

---



### **Markus Seibel**

Markus J Seibel, MD PhD FRACP is the Professor and Chair of Endocrinology at the University of Sydney. He heads the Department of Endocrinology & Metabolism at Concord Hospital and is the Director of the Bone Research Program at ANZAC Research Institute, Sydney. Professor Seibel is an active member of national and international professional societies and is on the Editorial Boards of various endocrine and bone journals. The focus of his clinical and research activities is the pathophysiology of bone metabolism in osteoporosis and metastatic bone disease. He has authored over 350 scientific articles, reviews, editorials and book chapters, and is the editor of six books.

---



### **Natalie Sims**

A/Prof Natalie Sims is director of the Bone Cell Biology and Disease Unit at St. Vincent's Institute (Melbourne), an NHMRC Senior Research Fellow and a Principal Research Fellow at The University of Melbourne. Her main research interest is local control of osteoblast and osteoclast function, particularly the roles of osteocytes, ephrins, PTH and gp130 signalling. Her goal is to identify pathways for new therapeutic options for bone and joint diseases. She is on the Editorial Board of BONE, a council member of ANZBMS, and board member of the International Society of Bone Morphometry and the International Bone and Mineral Society.

---



### **Nao Takahashi**

Prof. Nao Takahashi is Director of Institute for Oral Science and Dean of Graduate School of Dental Medicine in Matsumoto Dental University. Prof. Takahashi's research interest is the regulation of osteoclast differentiation and function. He established the coculture system of osteoblastic cells and hematopoietic cells for osteoclastogenesis, which is widely used for the study of osteoclast biology. Prof. Takahashi contributed to the cloning of osteoclast differentiation factor (RANKL). He has received academic awards from the Japanese Society for Bone and Mineral (1991) and from the Int. Bone and Mineral Society (2003). His current major interest is the characterization of osteoclast precursors in vivo. He has proposed a new concept "cell cycle-arrested quiescent osteoclast precursors" for in vivo osteoclastogenesis. He is an editorial board member of "Bone" and "Journal of Bone and Mineral Metabolism".

---



### **Hiroshi Takayanagi**

By combining experiences as an orthopaedic surgeon and an immunologist, Hiroshi Takayanagi studied in the laboratory of Professor Tadatsugu Taniguchi (University of Tokyo) the mechanism of bone destruction in rheumatoid arthritis, which focused on the regulation of osteoclasts by T cells. He has been Professor of Tokyo Medical and Dental University since 2003, and pursued this interdisciplinary field, osteoimmunology, which covers various researches on shared mechanisms and interactions between immune and bone systems. Since October 2009, Hiroshi has been the research director of Takayanagi Osteonetwork Project as Exploratory Research for Advanced Technology (ERATO) Program of Japan Science and Technology Corporation (JST).

---



### **Sunao Takeshita**

Sunao Takeshita PhD is a senior investigator of the Department of Bone and Joint Disease at National Center for Geriatrics and Gerontology, and Visiting Associate Professor of Department of Experimental Gerontology at the Nagoya City University. His main research interest is the molecular mechanism of osteoclast differentiation and bone resorption, especially signaling molecules linking osteoclasts to bone-forming osteoblasts. His goal is to elucidate the coupling mechanism of bone resorption to formation and apply the findings for the prevention of osteoporotic fracture.

---



### **Sakae Tanaka**

Sakae Tanaka graduated from University of Tokyo School of Medicine in 1987. He studied osteoclast biology in Department of Biochemistry, Showa University School of Dentistry from 1990 to 1993 (Professor Tatsuo Suda) and Department of Cell Biology, Yale University School of Medicine from 1993 to 1995, and earned his Ph.D. in orthopaedic surgery from University of Tokyo in 1996. He has been serving as Associate Professor in the Department of Orthopaedic Surgery, Faculty of Medicine, University of Tokyo since 2006. He has published widely and received academic awards from the American Society for Bone and Mineral Research and Japanese Society for Bone and Mineral Research. His clinical specialty is joint surgery and with interest includes shoulder, elbow, hip and knee surgeries. His scientific fields of interest are osteoclast biology, signal transduction and apoptosis.

---



### **Gethin Thomas**

Following his PhD studies at the University of Birmingham, UK and post-doctoral positions at UCSD with Professor Paul Price and at the Garvan Institute in Sydney with Professor John Eisman, Gethin Thomas spent 5 years in Montreal identifying and characterising novel bone genes with therapeutic potential in a small biotechnology company.

He returned to academia to work with Professor Matthew Brown at the Diamantina Institute in Brisbane to establish functional models in which to follow-up candidate genes identified from the genetic studies in osteoporosis and ankylosing spondylitis. We have now established a program combining genetic and genomic approaches together with functional studies in clinical samples and mouse models to fully characterise musculoskeletal diseases and identify and test novel therapeutic approaches.

---

### **Matt Warman**

Dr. Warman studied material science at Brown University and medicine at Cornell University Medical College. He completed an internship and residency in pediatrics at the Children's Hospital in Washington D.C., and a fellowship in medical genetics at the Children's Hospital in Boston. Following completion of his fellowship in 1989, he remained on staff as a clinical geneticist and also joined the laboratory of Dr. Bjorn Olsen at Harvard Medical School as a postdoctoral fellow. He subsequently joined the faculty at Case Western Reserve University School of Medicine. Dr. Warman is board certified in Pediatrics as well as in Clinical, Biochemical, and Molecular Genetics and maintains a strong clinical interest in these disciplines.

---



### **Tania Winzenberg**

Tania Winzenberg is a general practitioner and epidemiologist working as Senior Research Fellow at the Menzies Research Institute, University of Tasmania, Australia. After completing her PhD in 2006, she received the Australian and New Zealand Bone Mineral Society (ANZBMS)'s Kaye Ibbertson Award in 2007 for the best 5 papers in the field of metabolic bone disease published in the last 5 years for this work. She is first author of "Calcium and Other Nutrients During Growth" for the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (7th Ed). She regularly presents at key national and international primary care and bone conferences, with invited oral presentations at major meetings. She is actively involved in the ANZBMS including on the Professional Affairs Committee and the Research Committee. Her roles in the Royal Australian College of General Practitioners include Deputy Chair, National Standing Committee Research and on the working group on general practice guidelines for osteoporosis management.

---



### **Cory Xian**

Dr Cory Xian (NHMRC Senior Research Fellow, Professor of Bone Research, University of South Australia) obtained his PhD in 1993 from Murdoch University (Western Australia). He has been interested in research into tissue growth, injury repair and roles of growth factors/cytokines and progenitor cells. His earlier research positions include those at Child Health Research Institute, University of North Carolina at Chapel Hill, Flinders University, University of Adelaide, and Women's and Children's Hospital. Since 2001, he has been leading his research group conducting research on bone growth, growth plate injury repair, and cancer chemotherapy-induced bone defects. Dr Xian serves as editorial board member for 8 international scientific journals, and Associate Editors for *Int J Cell Biol* and for *Int J Oncol Res*.

---





### **Toshiyuki Yoneda**

Dr. Toshiyuki Yoneda, D.D.S., Ph.D. is currently the Professor and Chair of the Department of Biochemistry (1997-) and the Dean of Osaka University Graduate School of Dentistry, Osaka, Japan (2007-). Dr. Yoneda is also the President of the Japanese Society for Bone and Mineral Research (2009-) and a member of the Science Council of Japan (2005-). He was the Professor of the Dept. of Molecular and Cellular Biology at Medical Research Institute at Tokyo Medical and Dental University, Tokyo, Japan (2002-2003) and the Hyeser Professor of Division of Endocrinology and Metabolism, Dept. of Medicine at the University of Texas Health Science Center at San Antonio, TX, USA (2001-2009).



### **Andrew Zannettino**

A Zannettino is a Chief Medical Scientist, SA Pathology, and Professor of Medicine, University of Adelaide. His research efforts focus on the mechanisms of skeletal disease in myeloma. He has co-authored more than 120 publications, book chapters, review articles and patents and is a founding member of the Medical and Scientific Advisory Group of the Myeloma Foundation of Australia Inc.



### **Andreas Zankl**

Associate Professor Andreas Zankl is a clinical geneticist with a special interest in bone dysplasias. After completing his medical degree in Germany, he trained in Clinical Genetics in Switzerland and was a fellow at the International Skeletal Dysplasia Registry in Los Angeles, USA. In 2003 he became the clinical coordinator of the European Skeletal Dysplasia Network (ESDN). Since moving to Australia in 2006, he has established multidisciplinary bone dysplasia clinics at the Mater Children's Hospital and the Royal Children's Hospital in Brisbane. He has established a bone dysplasia research group at The University of Queensland's Centre for Clinical Research (UQCCR) and is an Associate Investigator at the Queensland Children's Medical Research Institute and The University of Queensland's Diamantina Institute.




### **Hala Zreiqat**

Professor Zreiqat is a National Health and Medical Senior Research Fellow and Head of the Tissue Engineering and Biomaterials Research Unit in the Faculty of Engineering, University of Sydney. She specializes in developing engineered novel new biomaterials and scaffolds for skeletal tissue applications, and in investigating their effect on in vitro and in vivo osteogenesis. She directs a diverse, multidisciplinary team of scientists, biomedical engineers and histologists with the aim of developing novel prosthetic devices and scaffolds for skeletal tissue regeneration; gaining greater understanding of bone/cartilage and endothelial cells biology when in contact with engineered biomaterials; and in turn providing therapeutic targets for the treatment of skeletal disorders. Prof. Zreiqat has published broadly and is a regular speaker at major scientific conferences. She is the president of the Australian and New Zealand Orthopaedic Research Society; Founder and Chair of Sydney University's Tissue Engineering Network and Co-founder of the Sydney Bone Group. She is on the editorial board of major journals in the field.

---

# IBMS-JSBMR 2013

May 28 to June 1, 2013



## 2nd Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research

**Kobe Convention Center &**  
(<http://kobe-cc.jp/english/index.html>)

**Kobe Portopia Hotel**

(<http://www.portopia.co.jp/en/index.html>)

# Kobe, Japan

### Organizing Committee

IBMS President

**Roger Bouillon, M.D., Ph.D.**

President

**Masaki Noda, M.D., Ph.D.**





# SPONSORS & EXHIBITORS

ANZBMS, IOF & JSBMR gratefully acknowledge the support of the sponsors *as of July 8, 2011*

## GOLD SPONSOR



## SILVER SPONSORS



in association with



## BRONZE SPONSORS



## EXHIBITORS



# TRADE DIRECTORY

## **AMGEN IN ASSOCIATION WITH GLAXOSMITHKLINE AUSTRALIA**

**Silver Sponsor**

[ausinfo@amgen.com](mailto:ausinfo@amgen.com) ■ [www.amgen.com](http://www.amgen.com) ■ [www.gsk.com.au](http://www.gsk.com.au)

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com).

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a proud history in Australia dating back to 1886. We collaborate with local researchers and doctors to discover new ways of treating and preventing disease, investing around \$45.2 million a year in research and development. We are pioneering new treatments for complex diseases like cancer, and we are leaders in vaccine technology and the treatment of respiratory disease, anti-viral, central nervous system and diabetes. We currently have over 30 discovery projects underway and our Medicines Research Unit is the only Phase 1 facility supported by a pharmaceutical company in Australia.

## **ASPEN PHARMACARE**

**Exhibitor**

[aspen@aspenpharmacare.com.au](mailto:aspen@aspenpharmacare.com.au) ■ [www.aspenpharma.com.au](http://www.aspenpharma.com.au)

Aspen Pharma Pty Ltd is a subsidiary of South African based Aspen International Pharmaceutical group. The company commenced operations in Australia in May 2001, with current annualized sales approaching \$800 million. Aspen's product range includes some of the most prescribed brands in Australia and includes, Evista, Elocon, Keflex, Klacid, Tritace, Triasyn, and the advanced technology wound care products – Flaminal Hydro and Flaminal Forte.

## **AUSTRALIAN AND NEW ZEALAND BONE AND MINERAL SOCIETY (ANZBMS)**

**Hosting Society**

[anzbms@racp.edu.au](mailto:anzbms@racp.edu.au) ■ [www.anzbms.org.au](http://www.anzbms.org.au)

Australian and New Zealand Bone and Mineral Society is a professional medical / scientific society established in 1989 to bring together clinical and experimental scientists and physicians actively involved in the study of bone and mineral metabolism in Australia and New Zealand. ANZBMS is the premier Australasian society in the field of bone and mineral metabolism which promotes excellence in bone and mineral research, fosters the integration of clinical and basic science, and facilitates the translation of our science to health care and clinical practice.

## **CHUGAI PHARMACEUTICAL CO., LTD.**

**Exhibitor**

[www.chugai-pharm.co.jp](http://www.chugai-pharm.co.jp)

Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products with global applications, focusing on the disease areas of oncology, renal disease, and bone and joint.

In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.

The consolidated sales in 2010 of Chugai totaled 379.5 billion yen and the operating profit was 66.2 billion yen. We are aiming at the consolidated sales of 460 billion yen and operating profit of 80 billion yen in 2012, as stated in mid-term business plan "Sunrise 2012". Additional information is available on at <http://www.chugai-pharm.co.jp/>.

## **ELI LILLY**

**Bronze Sponsor**

[au\\_info@lilly.com](mailto:au_info@lilly.com) ■ [www.lilly.com.au](http://www.lilly.com.au)

Eli Lilly and Company is a leading innovation-driven company with a growing portfolio of best-in-class and often first-in-class pharmaceutical products. Eli Lilly and Company exists to create answers that matter through innovative medicines, information, and exceptional customer service that enable people to live longer, healthier and more active lives.

## **HOLOGIC AUSTRALIA**

**Exhibitor**

[australia@hologic.com](mailto:australia@hologic.com) ■ [www.hologic.com](http://www.hologic.com)

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, mini C-arm imaging, cervical cancer screening, treatment for menorrhagia, and preterm birth screening.

## **INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF)**

**Hosting Society**

[info@iofbonehealth.org](mailto:info@iofbonehealth.org) ■ [www.iofbonehealth.org](http://www.iofbonehealth.org)

The International Osteoporosis Foundation (IOF) is a non-profit, nongovernmental umbrella organization dedicated to the worldwide fight against osteoporosis, the disease known as "the silent epidemic". IOF's members – committees of scientific researchers, patient, medical and research societies and industry representatives from around the world – share a common vision of a world without osteoporotic fractures. IOF now represents 199 societies in 93 locations.

## **JAPANESE SOCIETY FOR BONE AND MINERAL RESEARCH (JSBMR)**

**Hosting Society**

[jsbmr@ac-square.co.jp](mailto:jsbmr@ac-square.co.jp) ■ [jsbmr.umin.jp/eng/index.html](http://jsbmr.umin.jp/eng/index.html)

The Japanese Society for Bone and Mineral Research (JSBMR) is a professional medical/scientific society established to promote the study of problems pertaining to bones and other musculoskeletal tissues and mineral metabolism through annual scientific meetings and official Journal (Journal of Bone Mineral Metabolism).

## **KEY PHARMACEUTICALS**

**Exhibitor**

[otc@keypharm.com.au](mailto:otc@keypharm.com.au) ■ [www.keypharm.com.au](http://www.keypharm.com.au)

Key Pharmaceuticals, an Australian owned company markets OsteVit-D a range of Vitamin D3 1000 IU products in both tablets and convenient liquid form for patients who have difficulty swallowing. OsteVit-D & Calcium One-a-Day contains 600 mg of elemental calcium and 1000 IU of Vitamin D3 per tablet. Please call 1800 653 373 for samples.

## **MEDTRONIC**

**Exhibitor**

[anthony.c.swoboda@medtronic.com](mailto:anthony.c.swoboda@medtronic.com) ■ [www.medtronic.com.au](http://www.medtronic.com.au)

At Medtronic, we're committed to Innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. To do that, we're thinking beyond products and beyond the status quo - to continually find more ways to help people live better, longer.

## MSD

[www.msd-australia.com.au](http://www.msd-australia.com.au)

**Gold Sponsor**

Today's MSD is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. MSD. Be well. For more information, visit [www.msd-australia.com.au](http://www.msd-australia.com.au)

## NOVARTIS PHARMACEUTICALS

[www.novartis.com.au](http://www.novartis.com.au)

**Silver Sponsor**

Novartis is a world leader in the research, development and supply of products to protect and improve health and well-being. Our core businesses are in pharmaceuticals, consumer health (including eye-care and animal health), generics and vaccines. In Australia Novartis employs more than 600 people and invests over AUD \$30million annually in local research activities. Our name, derived from the Latin 'novae artes', means 'new skills' and reflects our focus on research and development to bring new treatments to patients and physicians world-wide.

## SANOFI-AVENTIS AND WARNER CHILCOTT

[www.sanofi-aventis.com.au](http://www.sanofi-aventis.com.au) ■ [www.wcrx.com](http://www.wcrx.com)

**Exhibitor**

The ambition of sanofi-aventis is to become a diversified global healthcare leader, focused on patients' needs. The largest pharmaceutical company in Europe and in emerging markets, sanofi-aventis is the fourth largest worldwide. The Group's vaccine division, sanofi pasteur, is the world leader for human vaccine production and commercialisation. Warner Chilcott is a leading specialty pharmaceutical company currently focused on gastroenterology, women's healthcare, dermatology and urology. Warner Chilcott is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Headquartered in Dublin, Ireland, Warner Chilcott has a presence in 13 countries in North America, Western Europe and Australia. The Company's manufacturing facilities are located in Puerto Rico, Northern Ireland and Germany.

## SERVIER

[info@au.netgrs.com](mailto:info@au.netgrs.com) ■ [www.servier.com.au](http://www.servier.com.au)

**Bronze Sponsor**

Servier is a privately owned pharmaceutical company with a long-standing commitment to research and development, with all profit from Servier worldwide operations channelled into research and development. Servier Australia's commercial interests are presently in cardiovascular disease (Coversyl – perindopril, Coversyl Plus – perindopril/indapamide, Coveram – perindopril/amlodipine, Coralan - ivabradine), diabetes (Diamicron 60mg MR - gliclazide), and postmenopausal osteoporosis (Protos – strontium ranelate).

## THOMSON SCIENTIFIC INSTRUMENTS

[info@tsi.com.au](mailto:info@tsi.com.au) ■ [www.tsi.com.au](http://www.tsi.com.au)

**Exhibitor**


Thomson Scientific Instruments Pty Ltd (TSI) have been serving the global science community since 1980. In Australia, TSI currently represents innovative manufacturers such as Skyscan, Gatan, Omicron Nanotechnology and nanoFACTORY Instruments. See: [www.tsi.com.au](http://www.tsi.com.au)

# PROTOS®

strontium ranelate

**PBS LISTED**  
for both primary\*  
& secondary fracture\*  
prevention in women with  
postmenopausal osteoporosis!  
\*age ≥70, T-score ≤-3.0

- Improved bone **micro-architecture** after 3 years compared to placebo<sup>2</sup>
- Decreased risk of both **vertebral and non-vertebral (incl. hip) fractures**<sup>3,4</sup>
- A **safety profile** that extends **out to 8 years**<sup>5</sup>



Please refer to Approved Product Information before prescribing.

**PROTOS® Abridged Product Information. Indications:** treatment of postmenopausal osteoporosis to reduce the risk of fracture. **Contraindications:** known hypersensitivity to strontium ranelate or to any of the excipients. Severe renal impairment. **Precautions:** use with caution in patients at increased risk of VTE, including patients with a past history of VTE. PROTOS contains aspartame, a source of phenylalanine, which may be harmful for people with phenylketonuria. Category B3. Do not use in pregnancy. **Discontinue in case of allergic reaction-permanently if rash occurs.** **Interactions:** should preferably be taken >2 hours after: - food, milk, milk products, or medicines containing calcium, which may reduce bioavailability. Suspend during treatment with oral tetracycline and quinolone antibiotics, as may reduce absorption of these drugs. Concomitant bisphosphonate treatment is not recommended. No known interaction with oral vitamin D. **Adverse Reactions:** headache, disturbances in consciousness, memory loss, nausea, diarrhoea, loose stools, dermatitis, eczema. Less common reactions- consult Approved Product Information. **Post Marketing Adverse Reactions:** \*bronchial hyperreactivity, \*toxic epidermal necrolysis, hypersensitivity reactions, pyrexia (with hypersensitivity skin reactions), serum transaminase increase (with hypersensitivity skin reactions), musculoskeletal pain, peripheral oedema. **Dosage and Administration:** one 2g sachet once daily by mouth preferably at bedtime or > 2 hours after food. No dosage adjustment required in the very elderly, mild to moderate renal impairment, or hepatic impairment. **Presentation:** PROTOS 2g sachets contain 2g strontium ranelate as a yellow powder. Boxes contain 7 or 28 sachets. **Date of Preparation:** 23 December 2010. Full Approved PI is available on request from Servier Laboratories (Australia) Pty. Ltd. 8 Cato Street Hawthorn, VIC 3122. Customer Service (Toll Free) 1800 33 1675. **PBS Dispensed Price – January 2011: \$53.34, 28 + 5 repeats.**

\*Please note changes in Product Information.

1. Pharmaceutical Benefits Schedule January 2011 2. Arlot M et al *JBM* 2008;23:215-222 3. Meunier PJ, Roux C, Seeman E, et al *NEJM* 2004;350:459-468 4. Reginster JY, Seeman E, De Vernejoul MC et al *J Clin Endocrinol Metabolism* 2005;90:2816-2822 5. Protos Approved Product Information.

PBS Information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.



# VENUE INFORMATION

## **GOLD COAST CONVENTION AND EXHIBITION CENTRE**

Australia's largest regional convention centre, the Gold Coast Convention and Exhibition Centre is conveniently located in the heart of the Gold Coast. The GCCEC has become one of the first convention facilities in Australia to achieve the prestigious EarthCheck Silver Certified status, which recognises the Centre's commitment to operating at the world's highest environmental standards.

## **TRANSPORTATION TO THE MEETING VENUE**

Please refer to page 37 for comprehensive Transportation Information.

## **VENUE MAP**

Please refer to inner back cover for a detailed map of the Meeting Venue including Plenary, Meet-the-Expert and Session rooms, poster, exhibition and social function areas.



## **GOLD COAST CONVENTION AND EXHIBITION CENTRE (GCCEC)**

Corner Gold Coast Highway & TE Peters Drive

Broadbeach, Queensland 4218, Australia

**T** +61 7 5504 4000

**F** +61 7 5504 4001

[www.gccec.com.au](http://www.gccec.com.au)





## DATES AND OPERATING HOURS

DATES	VENUE	REGISTRATION	PLENARY	SATELLITE SYMPOSIA	MEET-THE-EXPERT	POSTER SESSION	ORAL PRESENTATION	EXHIBITION	SOCIAL FUNCTIONS
SUN SEPT 4	09:00-20:00	13:00-18:00	<b>Opening</b> 16:00-17:45					17:45-19:30	<b>Welcome Reception</b> 17:45-19:30
MON 5	07:00-20:00	07:00-18:00	08:30-12:00 14:30-17:30	07:30-08:30 12:30-13:30 17:30-18:30	07:30-08:30	13:30-14:30	10:20-17:30	08:30-17:30	<b>Zumba Fitness Class</b> 18:30-19:30
TUES 6	07:00-20:00	07:00-18:30	08:30-12:00 14:30-18:30	12:35-13:35 18:30-19:30	07:30-08:30	13:35-14:30	14:30-18:30	08:30-18:30	<b>Women in Bone Function</b> 07:30-08:30 <b>YI BBQ Buffet</b> 19:30-22:00
WED 7	07:00-23:30	07:00-18:00	08:30-12:00 14:00-18:00	13:00-14:00	07:30-08:30		16:15-17:55	08:30-17:30	<b>Student Mentor Breakfast</b> 07:30-08:30 <b>Gala Dinner</b> 19:30-23:00
THURS 8	07:00-14:00	08:30-13:30	09:00-12:45 <b>Closing</b> 12:45-13:15				09:00-10:45		<b>Beach Breakfast</b> 07:00-08:15

As of July 8, 2011 • Subject to change

### CAR PARKING

The cost of parking under the Convention and Exhibition Centre is AU\$ 10 per vehicle per exit. The car park entrance is at the northern end of the building, accessible from traffic lights off the Gold Coast Highway and the main driveway off TE Peters Drive.

### CASH DISPENSER / ATM

There are 2 Cash Dispensers/ATM's located within the GCCEC. One is located in the main entrance foyer and another is located in the central foyer (next to the lift).

### CHILDREN

Delegates are asked to refrain from taking children and accompanying persons to any scientific session. Registered guests and children (as accompanying persons) are welcome to relax in the various rest areas, however, children under the age of 12 must be accompanied and supervised by an adult at all times. Please contact the hotel's housekeeping for assistance on babysitting facilities.

### DRESS CODE

Dress is informal throughout the entire Meeting. The conference organising committee, however, reserves the right to refuse access when deemed necessary for the comfort and safety of all delegates.

### FIRST AID

All of the GCCEC security personnel are first aid trained. Any first aid requirements please see the nearest staff member and they will contact the nearest security staff member available.

### INFORMATION DESK

The information desk for the Gold Coast Convention and Exhibition Centre is located in main entrance foyer. For all lost and found enquiries, please visit the information desk and that centre staff will be able to assist. Opening times for the desk are 08.30-17.00.

### INSURANCE AND LIABILITY

The Meeting Organisers (IOF and ANZBMS), the Meeting Venue (Gold Coast Convention and Exhibition Centre), the Meeting Secretariat (ASN Events) and any suppliers, representatives or agents linked to the organisation of the Meeting shall not be held

liable by any person for any injury, damage, theft, loss, medical problem or inconvenience which may be suffered by any person while traveling to or from, or during such person's presence in Australia in connection with this Meeting. Participants and their guests are advised to purchase their own insurance against any such occurrences.

### **INTERNET CORNER**

The Internet Corner is available for all delegates in the Exhibition and Poster Area. Delegates using the Internet Corner service must restrict their access time to 15 minutes whenever there is a queue.

### **LANGUAGE**

English is the official Meeting language. No translation is provided.

### **LUNCHEES AND COFFEE BREAKS**

Official lunches and coffee breaks will be provided in the Exhibition and Poster Area.

### **MESSAGE BOARD**

A message board will be available at the registration desk on the first floor foyer.

### **MOBILE PHONES**

Please be respectful of speakers and fellow delegates and switch off mobile devices during all sessions.

### **NO-SMOKING**

The Gold Coast Convention and Exhibition Centre is a not-smoking venue. As per Queensland law, smoking is prohibited within 4 meters of any entrance to the building.

### **SECURITY AND EMERGENCY PROCEDURES**

In case of an emergency - dial (the call is free within Australia):

Ambulance: 000

Police: 000

Fire: 000


Any security problems or concerns should be reported to the Convention Centre security staff. The staff will handle any emergency situation and everyone is asked to follow the instructions announced over the loudspeaker system. Emergency exits are marked with green exit signs.

### **SPECIAL ACCESSIBILITY**


If you require special arrangements in order to participate fully in the Meeting, please contact the Meeting Secretariat.

# Anabolic power<sup>1-3</sup> to rebuild bone<sup>1</sup>

## Anabolic bone remodelling effect of FORTEO<sup>4</sup>



Baseline



Same patient after 21 months\*

MicroCT images are of paired iliac crest bone biopsies at baseline and after 21 months\* of treatment with FORTEO. This study presents quantitative microstructural data from a substudy of the Fracture Prevention Trial (FPT). 102 patients were randomized to placebo or teriparatide injections and underwent iliac crest biopsies before and after teriparatide administration. 51 paired iliac crest biopsy specimens of sufficient quality for analysis were obtained from subjects at 11 sites in five countries from the FPT. These biopsies are representative of a patient treated with 20mcg over 21 months\* in the trial.<sup>4,5</sup>

\*Note: The maximum registered lifetime treatment duration of FORTEO is 18 months. †Severe: ~40% reduction in vert height, SQ grade 3.<sup>5,6</sup> Moderate: ~26-40% reduction in vert height, SQ grade 2.<sup>5,6</sup>

- FORTEO reduces the risk of multiple new vertebral and non-vertebral fragility fractures<sup>5</sup>
- 18 months after discontinuation of 21 month\* therapy, the risk of moderate to severe<sup>†</sup> vertebral fractures was reduced by 57%<sup>6</sup>
- 18 months after discontinuation of 21 month\* therapy, the risk of 1 or more new vertebral fractures was reduced by 41%<sup>6</sup>
- 30 months after discontinuation of 19 month\* therapy, reductions in non-vertebral fractures were well preserved compared to baseline<sup>7</sup>

### WARNING.

In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times exposure in humans given a 20 mcg dose and occurred after treatment durations ranging from 6 to 24 months. Effects were dependent on dose and duration of treatment, but a no-effect dose was not determined. The relevance of the rat osteosarcoma findings to humans has not yet been established.

PBS Information: Authority Required. Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who: a) has a bone mineral density (BMD) T-score of -3.0 or less, and b) has had two or more fractures due to minimal trauma, and c) has experienced at least one symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses. Refer to the PBS schedule for full criteria.

Please review full Product Information before prescribing; available from the trade display.

References: 1. Canalis E, Giustina A and Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. *N Engl J Med* 2007; 357:905-916. 2. Arlot M et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. *J Bone Miner Res* 2005; 20:1244-1253. 3. McClung MR et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. *Arch Intern Med*. 2005; 165:1762-1768. 4. Jiang Y et al. Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. *J Bone Miner Res* 2003; 18:1932-1941. 5. Neer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001; 344:1434-1441. 6. Lindsay R et al. Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis. *Arch Intern Med* 2004; 164(18):2024-2030. 7. Prince R et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. *J Bone Miner Res* 2005; 20:1507-1513. Eli Lilly Australia Pty Limited, ABN 39 000 233 992 112 Wharf Road, West Ryde, NSW 2114. AUFRT00113 S&H 07/11 LILFO0009.



**FORTEO**<sup>®</sup>  
teriparatide (rbe)



## ABOUT GOLD COAST, QUEENSLAND

The Gold Coast is Australia's premier tourist destination and has been nominated as one of the most desirable places to live in the world. It is Australia's largest regional city and is bordered by 70 km of beaches and rainforest. The Gold Coast is 80 km from Brisbane (the state capital) and is located in South Eastern Queensland. Over 466,000 people live on the Gold Coast. Famous for its theme parks, stunning beaches and subtropical rainforests, the Gold Coast boasts 70 kilometres of uninterrupted coastline and 26 patrolled beaches.

The Gold Coast is the theme park capital, with parks such as Sea World, Dreamworld, Movie World and Wet 'N' Wild entertaining families all year round. There is also a chance to see native wildlife at the Currumbin Wildlife Sanctuary and David Fleay Wildlife Park. For more information on attractions please visit Gold Coast Tourism [www.visitgoldcoast.com/attractions](http://www.visitgoldcoast.com/attractions)

**Currumbin Wildlife Sanctuary** [www.cws.org.au](http://www.cws.org.au)

**David Fleay Wildlife Park** [www.derm.qld.gov.au/wildlife-ecosystems/wildlife/david\\_fleay\\_wildlife\\_park](http://www.derm.qld.gov.au/wildlife-ecosystems/wildlife/david_fleay_wildlife_park)

**Dreamworld** [www.dreamworld.com.au](http://www.dreamworld.com.au)

**Movie World** [www.movieworld.com.au](http://www.movieworld.com.au)

**Sea World** [www.seaworld.com.au](http://www.seaworld.com.au)

**Wet 'N' Wild** [www.wetnwild.com.au](http://www.wetnwild.com.au)

For further information about Australia, Queensland and the Gold Coast, please visit the following tourism sites.  
[www.australia.com](http://www.australia.com) ■ [www.goldcoasttourism.com.au](http://www.goldcoasttourism.com.au) ■ [www.queenslandholidays.com.au](http://www.queenslandholidays.com.au)





# TRAVEL INFORMATION

## TRAVELLING BY PLANE

The Gold Coast has its own domestic airport at Coolangatta, just 20 minutes south of the Gold Coast Convention and Exhibition Centre with regular flights from all capital cities. Services are provided domestically by three airlines, Virgin Blue, Tiger and Jetstar, and internationally through multiple Airlines. Brisbane International Airport is located just one hour drive from Broadbeach.

## TRAVELLING BY TRAIN

Train services require a coach, shuttle or vehicle transfer. Interstate trains terminate in Brisbane at the Roma Street Transit Terminal 60 minutes north of Surfers Paradise. Trains traveling from Sydney terminate in Mulwillumbah, 30 minutes south of Surfers Paradise. The City Train runs regularly from Brisbane with stops at Coomera, Helensvale, Nerang and Robina. Nerang or Robina stations are the best stops to get off at as they are closest to the GCCEC (Nerang station is slightly closer to the GCCEC).

## TRAVELLING BY CAR

When traveling southbound from Brisbane (80 km) take the Broadbeach Motorway Exit and follow the directions to Broadbeach. Just after the Pacific Fair Shopping Centre turn left at the next set of lights. This will bring you out onto the Gold Coast Highway. The Gold Coast Convention and Exhibition Centre is situated on the corner of the next street, just after Jupiter's Casino.

The Gold Coast is 900 km north of Sydney and is accessible by either the Pacific Highway or the inland New England Highway. There is a wide range of coach / bus transfers, taxi and hire car services available from the airports.

The Gold Coast Convention and Exhibition Centre's car park entrance is at the northern end of the building, accessible from traffic lights off the Gold Coast Highway and the main driveway off TE Peters Drive. Undercover car spaces are available for short-term parking. An AU\$ 10 inclusive of GST flat rate is charged for car parking at the centre (1 exit only). The car park will be open 24 hours, 7 days a week. Please check with the venue for further details.

## TRAVELLING BY TAXI

There is a taxi rank available directly outside the airport terminal. You can also pre-book a taxi, the number to dial is Gold Coast Cabs - 131 008. Taxis are also readily available in Broadbeach with a taxi rank also located at the Gold Coast Convention and Exhibition Centre. A taxi fare from the Coolangatta Airport to Broadbeach is approximately AU\$ 40-50. Travelling from Broadbeach to the Gold Coast City Centre (Cavill Avenue) is approximately AU\$ 10-20.

## GOLD COAST TOURIST AND AIRPORT SHUTTLE

The Gold Coast Tourist Shuttle runs from the Coolangatta Airport and will drop you off at your hotel. The shuttle also provides transfers from your hotel to Theme Parks. A one way fare from the airport to your hotel is AU\$ 19 for an adult. To book a shuttle space please visit [www.gcshuttle.com.au](http://www.gcshuttle.com.au)

Various coach alternatives are available between Brisbane Airport and the Meeting Venue.





# PRACTICAL INFORMATION

## CLIMATE AND CLOTHING

The Gold Coast has a sub-tropical climate with plenty of sunshine year round (an average of 300 days a year). September is the beginning of spring and temperatures average around 15-25°C / 59-77°F.

Australia is a relaxed and casual place. The rule for most establishments is 'enclosed footwear'. Sneakers, joggers, sandshoes, and sandals are fine for both men and women except in up-market restaurants and exclusive nightclubs. A jacket may be required in some nightclubs and restaurants.

## COMMUNICATION

In order to make international calls to Australia, dial the international code +61 and the correspondent's number.

## CURRENCY/CREDIT/CHARGE CARDS/BANKS

The currency is Australian dollars and cents (AUD). The Australian dollar is divided into 100 cents. One and two cent coins are no longer in circulation, but many items in shops and supermarkets are priced in odd amounts, such as \$1.97 or \$9.99. The law provides that the TOTAL bill is rounded up or down to the nearest 5 cents. So \$19.97 becomes \$19.95, \$19.98 becomes \$20.00. Coin denominations are 5c, 10c, 20c, 50c, \$1 and \$2. Notes are \$5, \$10, \$20, \$50 and \$100, are colour coded and made from a plastic compound that will survive a wash or a swim.

Visa, Mastercard, American Express and Diners Club are very widely accepted. All banks have automated teller machines (ATMs) accessible 24-hours a day, generally outside the branch or in the foyer. If one bank doesn't accept your card, chances are the next one will, and all banks have the facility of being able to deal with a real person during business hours (09:00-16:00, Monday to Friday).

Traveller's cheques, especially in foreign currencies, are generally not accepted except by hotels, large stores and tourist shops. Those that do, display a 'traveller's cheques welcome' sign. For the best exchange rate, cash your cheques at a bank or Bureau de Change rather than a hotel. The same holds true for foreign currency, which is not generally accepted by Australian businesses and shops.

## ELECTRICITY

240/250 volts AC 50HZ. Australia uses the Type I electrical socket, and this usually has a switch for extra safety. There is an unearthed version of the Type I plug, but the sockets are always three-pinned. There are several Australian plug variants, including a 15 A, 20 A, 25 A and 32 A. Universal outlets for 110 volts (shavers only) are standard in hotels, apartments and motels.

## GRATUITIES

No service charge applies in Australia. Tipping is not mandatory but a 10% tip in restaurants and hotel bars is normal for good service. Waiters and waitresses do not rely on tips for their income, but tips are an incentive to perform well. Bar staff in pubs are happy with loose change. Taxi drivers do not expect tips, but it is usual to 'round-up' the fare to the nearest dollar.

## LANGUAGE

English is the official language of Australia and the conference.

## PHARMACIES

Pharmacies are readily available. Prescription medicines can be purchased from registered pharmacists that are generally open from 09:00 to 17:00.



## SUN, SURF, SAFETY

The majority of Australian beaches have golden sand and clean water but conditions can be deceptive. Most of the major beaches are patrolled by lifeguards but there are many beautiful beaches that are often deserted and look very inviting on a warm day. If you are not a strong swimmer used to surf, stay out and find another beach or use the hotel pool.

Safe swimming areas are marked by a pair of flags, half red half yellow, on either side of the safety zone. Stay between the flags and keep an eye on the lifeguard. He or she may move the flags from time to time as conditions change and may need to wave you back into the safety zone. If you are in any doubt, ask the lifeguard. Many visitors who get into trouble with the surf come from countries where a flagged area denotes a private beach. There are no private beaches in Australia. One tip when out swimming between the flags is to align yourself with a fixed landmark on the shore - a tree, the clubhouse etc. - and check occasionally that the surf is not subtly moving you away from the patrolled area. If you do get caught in a rip, do not fight against it but go with it and slowly make your way across it to the beach.

Sharks: Australia has several species of dangerous sharks, though they rarely approach swimmers. The Shark Control Programme run by the Queensland Government manages a range of nets and other preventative measures designed to keep sharks away from people swimming at the beach. There has not been a fatal shark attack in the waters off the Gold Coast since 1964. Lifesavers patrolled beaches keep a watch and sound a warning if a shark is sighted.

Sun Protection: Australia has one of the highest rates of skin cancer in the world caused by exposure to the sun. Make sure you use a sunscreen with a Sun Protection Factor (SPF) of at least 15+ and apply it often.

## PERSONAL SAFETY

Australia is a safe destination but as with anywhere in the world, there is petty crime. Police operate under strict guidelines and are polite and friendly.

Provided you have a driver's licence or some form of 'official' ID, leave your passport in the hotel safety deposit or your in-room safe. In the event of an accident, it is wise to carry some form of identification together with the name of your hotel or a friend or relative's address. Include something that will make it clear if you have an illness requiring special drugs or you are allergic to life-saving substances like Penicillin.

If you have a car, do not leave valuables or parcels and bags that may appear to be valuable in view.

## SMOKING RESTRICTIONS

Smoking is not permitted in totally enclosed areas or outdoor/part-enclosed public areas with food/drink service, gaming, or live entertainment. Nightclubs, bars and pubs have designated smoking zones. Playgrounds, swimming/sport/recreation areas are also smoke free by law. There are on the spot fines for being caught.

# REGISTRATION INFORMATION

## REGISTRATION DESCRIPTION

The registration fee entitles the registered participant to the following:

- Admission to all Plenary Sessions, Satellite Symposia, Poster Sessions and Exhibition Area
- One copy of the Programme & Abstract Book
- A bag containing official material and a Meeting badge
- A certificate of attendance – available on request
- Coffee breaks & lunches
- Opening Ceremony and Welcome Reception
- Zumba Fitness Class (pre-registration is essential)
- Goods and Services Tax (GST)

The registration fee does not include:

- Airport transfers
- Local transportation to the Meeting Venue
- Other meals & drinks, such as Meet-the-Expert Sessions, Gala Dinner, Beach Breakfast, Women in Bone Function, Young Investigator BBQ and Student-Mentor Breakfast
- Accommodation
- Excursions
- Insurance

## CANCELLATION POLICY

No refund is payable for cancellation of registration. However, registrations can be transferred to substitute delegates without penalty. Please advise the registration desk of any changes.

## NAME BADGES

All persons attending any function of the Meeting are kindly requested to wear their badges during all Meeting activities including Social Events and Exhibition. Entry will not be permitted without a badge, nor with blank badges or substitutes.

## CERTIFICATE OF ATTENDANCE


Certificates of Attendance will be available on request at the registration desk. Please ensure that you have your badge with you and that your name is correctly written on it.

## CANCELLATION OR MODIFICATION OF THE CONGRESS DUE TO FORCE MAJEURE

In case of force majeure, the Meeting Organisers (IOF and ANZBMS) have the right to alter or cancel the Meeting without prior notice, however a notice of the occurrence shall be given by IOF and ANZBMS as soon as reasonably possible. Force majeure shall mean any circumstance beyond the reasonable control of IOF and ANZBMS which prevents or impedes the holding of the Meeting, including, but not limited to, government action, war or hostilities, riot or civil commotion, plague or other epidemic such as SARS, bird flu etc., earthquake, flood, hurricane, cyclone, fire or other natural physical disaster, explosion, accident or breakdown, strike, lack of the usual means of transportation or terrorism or due to events which are not attributable to wrongful intent or gross negligence of the IOF and ANZBMS. IOF and ANZBMS shall not be liable for any direct or indirect, incidental or consequential damages, losses, expenditures or any other inconveniences or costs caused by such modification or cancellation of the Meeting. Furthermore, registration fees will not be reimbursed by IOF and ANZBMS.

## DISCLAIMER

All reasonable endeavours will be made to hold the Meeting and to present its programme as scheduled under circumstances which assure the comfort and safety of all participants and their guests. However, the IOF and ANZBMS reserve the right to modify the programme, unilaterally and without notice. Neither IOF and ANZBMS, nor their officers, directors, employees, representatives or agents, shall be held liable by any person as a result of the cancellation of the Meeting or any of the arrangements, programs or plans connected therewith, or for any injury, damage or inconvenience which may be suffered by any person while travelling to or from, or during such person's presence in Australia in connection with this Meeting. Participants and their guests are advised to purchase their own insurance against any such occurrences.





# IOF Regionals **Brazil** 12

1<sup>st</sup> Latin America Osteoporosis Meeting

**24-27 May 2012**

WTC CONVENTION CENTER • SÃO PAULO, BRAZIL



## Scientific Programme Committee Co-Chairs

▪ Prof. Cyrus Cooper ▪ Dr. José Zanchetta ▪ Dr. Sergio Ragi-Eis

## Meeting Secretariat

International Osteoporosis Foundation

9, Rue Juste-Olivier • CH – 1260 Nyon • Switzerland

T +41 22 994 0100 • F +41 22 994 0101

*brazil2012@iofbonehealth.org*

Abstract Submission Deadline

**16 DECEMBER 2011**

Early-bird Registration Deadline

**15 MARCH 2012**





# SOCIAL EVENTS

AS OF JUNE 30, 2011 • SUBJECT TO CHANGE

## WELCOME RECEPTION

**Sunday September 4, 2011 (17:45-19:30)**

All delegates, exhibitors and partners that have purchased a partner welcome function ticket are invited to attend the Welcome Reception, beginning at 17:45 in the Exhibition Hall. Finger food and drinks will be served, with an array of entertainment including:

- **Roaming Animals** Currumbin Zoo will be showcasing some of Australia's native animals. All handling instructions will be given by the wildlife handler on the day at the time of handling and will be able to provide all details you may want to know about the animal. Taking photographs of the animals is allowed.
- **Indigenous Dancers** Jaran Dancers will provide some authentic Aboriginal dance and music for you to enjoy.
- **Bush Band** Bushfire will be providing some authentic Australian bush music. Feel free to sing and dance along!

Along with the entertainment, the Local Organising Committee has also arranged for some patrol members from the **Kurrawa Surf Life Saving Club** to provide water safety tips for swimming in the beaches. Look out for the stand and patrol members in the Exhibition Area.

If you would like to purchase a welcome function ticket for your partner, please visit the registration desk.



## ZUMBA FITNESS CLASS

**Monday September 5, 2011 (18:30-19:30)**

All delegates are welcome to take part in the new fitness craze ZUMBA! The class will commence at 18:30 in **Room 5 & 6**. You should wear comfortable clothes that are easy to move around in and bring plenty of water. If you would like to take part and have not advised the Meeting Secretariat, please visit the registration desk for availability. Zumba Gold Coast started the first Zumba classes on the Gold Coast in August 2009. Zumba Gold Coast prides itself on having some of the most experienced and energetic instructors and classes in the area. Zumba classes fuse hypnotic Latin and hip-hop rhythms in easy-to-follow dance moves. Zumba allows you to let loose, rock-out, have a blast and burn calories — this is what the Zumba programme is about and it is addictive. So if you love dancing or working out and want to experience a calorie-burning blast that is fun, all you need to do is try the class.

## WOMEN IN BONE FUNCTION

**Tuesday September 6, 2011 (07:30-08:30)**

The Local Organizing Committee is delighted that Chancellor Leneen Forde will be presenting at the Women in Bone Function. The function will be a breakfast session starting at 07:30 AM and held in **Plenary Lecture Room, Arena 1B**. Chancellor Forde will be discussing, "Does a successful career in science assume a choice between a research career and being a 'primary carer'?" If you would like to attend and have not advised the Meeting Secretariat, please visit the registration desk. The cost to attend is AU\$10.

Chancellor Forde was born in Canada, coming to Australia in 1954. She began her career as a Medical Laboratory Technician in Ontario, Canada, upon receipt of a Diploma of Medical Technology in 1953. From 1954 to 1956, she was employed by the Haematology Department of the Royal Brisbane Hospital. She changed career paths, and in 1970, Chancellor Forde studied for her law degree whilst juggling the care of her five children, and pursued her law career, helping to establish the Queensland Women Lawyers Association. Named Queenslander of the Year in 1991 for her work in advancing the social and economic welfare of Queenslanders, and in particular her contribution to the advancement of women, Chancellor Forde was appointed as Queensland's first woman Governor and the first Governor to be appointed by the Queen



on the advice of the Queensland Government. She is currently Vice President Scouts Australia and Board Member, Queensland Ballet Board, All Hallows School Council and Queensland Community Foundation Board of Governors. She serves as patron of Rosies, Karuna Hospice Service, Alzheimer's Association of Australia (Darling Downs and South West Inc) and the Forde Foundation. She was elected as Chancellor of Griffith University in June 2000.

### YOUNG INVESTIGATOR BBQ BUFFET

**Tuesday September 6, 2011 (19:30-22:00)**

The BBQ Buffet will be held at **Kurrawa Surf Life Saving Club** and will be a great chance for Young Investigators to socialise. Tickets will be AU\$10 per person and includes your buffet dinner. Drinks will need to be purchased. If you have not yet secured your ticket, please visit the registration desk for availability.

### STUDENT-MENTOR BREAKFAST

**Wednesday September 7, 2011 (07:30-08:30)**

**"BUILDING A CAREER IN SKELETAL RESEARCH: FROM FOUNDATIONS TO PENTHOUSE SUITE"**

This is a great opportunity for students to network with senior members of the field. There will be presentations from Allison Pettit and Matthew Gillespie which will then be followed by discussion. The breakfast will start at 07:30 AM and will be held in the **Plenary Lecture Room, Arena 1B**. Tickets are AU\$10; if you have not yet purchased a ticket, please visit the registration desk for availability.

### GALA DINNER-DANCE

**Wednesday September 7, 2011 (19:30-23:00)**

The Gala Dinner-Dance will be held from 19:30 in **Arena 2**. A three course meal will be served and a band has been booked for you to dance the night away. Tickets are AU\$70 for registered delegates and AU\$110 for additional tickets purchased. If you would like to attend and have not advised the Meeting Secretariat, please visit the registration desk for availability.

### BEACH BREAKFAST

**Thursday September 8, 2011 (07:00-08:15)**

A Beach Breakfast has been organised at the **Kurrawa Surf Life Saving Club (SLSC)**, which will be commencing at 07:00 to 08:15 AM. For those delegates that would also like to participate, there will be a group of delegates going for a morning stroll/ run along the beach. The group will start off from the Kurrawa SLSC and return to the SLSC. A map of how to get from the Gold Coast Convention Centre to the SLSC is below:

Directions for walking to the Kurrawa SLSC:

*approximately 8 minutes*

1. Head south on Gold Coast Highway towards T E Peters Drive
2. Turn left onto Victoria Avenue
3. At the roundabout, take the second exit and head through the Broadbeach Mall
4. At the end of the mall, cross Old Burleigh Road
5. Kurrawa SLSC will be located on your right

*Tickets for the beach breakfast are AU\$10 each. Please visit the registration desk for availability if you have not purchased a ticket and would like to participate.*



# SCIENTIFIC SESSIONS INFORMATION

## MEET-THE-EXPERT SESSIONS

All delegates are able to select to attend a large number of Meet-the-Expert Sessions (subject to availability). Tickets to attend are AU\$15 and include breakfast. Please visit the registration desk for availability in each session if you have not secured your place.

MONDAY SEPT 5, 2011 7:30-08:30	TUESDAY SEPT 6, 2011 07:30-08:30	WEDNESDAY SEPT 7, 2011 07:30-08:30
<b>Neil Binkley</b> Vitamin D, common sense and the Goldilocks principle	<b>Cyrus Cooper</b> Vertebral fracture: Definition, clinical impact and epidemiology considerations	<b>Jillian Cornish</b> How does adipose tissue affect the skeleton? Laboratory studies
<b>John A. Kanis</b> Economic evaluation of osteoporosis	<b>Shigeaki Kato</b> The role of the Vitamin D receptor in bone health	<b>Steve Goldring</b> Bone and cartilage pathophysiology in osteoarthritis: Therapeutic implications
<b>Matthew Warman</b> Genetics in the dissection of bone biology	<b>Stuart Ralston</b> Osteoporosis: When to measure, what to measure, whom to treat and with what?	<b>Toshio Matsumoto</b> Vitamin D derivatives
<b>Toshiyuki Yoneda</b> Cancer and bone	<b>Sakae Tanaka</b> Rheumatoid arthritis and bone	<b>Eric Orwoll</b> Sex steroids and bone in men: What to measure, what to treat?

## POSTER VIEWING

Posters can be viewed in the Exhibition Area during 08:30-17:30 from Monday September 5 to Wednesday September 7.

## POSTER PRESENTATION

Presenting authors should be present at their posters during 13:30 to 14:30 according to the following schedule:

Poster number	Poster presentation date
Odd	Monday September 5
Even	Tuesday September 6

Posters can be placed on the poster boards from 17:45 on Sunday September 4, 2011 and must be removed by afternoon tea on Wednesday September 7, 2011. You can find your correct position for your poster by finding the appropriate abstract number on the display panels. The poster listing provides your abstract number which is how you find your placement position. Poster presenters can attach their poster to the panels provided with Velcro, additional supplies of Velcro can be obtained from the registration desk. All posters should be 1 m wide by 1.2 m high.

## SPEAKER PREVIEW ROOM

Oral presenters can load their talks in the speaker preview room. It is located in Room 3 on the first floor and there will be an Audio-Visual technician on hand to load your presentation. Please ensure you visit the speaker preview room well in advance of your session to load your presentation (at least 120 minutes). It is advised that you load your presentation no later than one session before you are scheduled to present.

## Hours of Operation (as of June 30, 2011)

Sunday September 4, 2011	15:00-17:45	Monday September 5, 2011	07:00-17:30
Tuesday September 6, 2011	07:00-18:30	Wednesday September 7, 2011	07:00-18:15
Thursday September 8, 2011	08:00-11:30		

# IOF YOUNG INVESTIGATOR AWARD

IOF is dedicated to advancing scientific knowledge on osteoporosis, and in particular to encouraging young researchers in all parts of the world to focus on this important area of research. As a sign of this commitment, IOF is offering IOF Young Investigator Awards to the authors, aged 40 or under, of the top eight ranking abstracts submitted to the **IOF Regionals 2<sup>nd</sup> Asia-Pacific Osteoporosis and Bone Meeting**. The following recipients are presenting their work at a special oral session on Monday September 5, 2011 starting at 10:20-12:00 in **Room 5 & 6**.

- Agnieszka Arthur *Australia*
- Haslinda Gould *Australia*
- Shozo Itoh *Japan*
- Masanobu Kawai *Japan*
- Arei Miyamoto *Japan*
- Krishanu Mondal *India*
- Zhifeng Sheng *China*
- Rikako Takashima *Japan*

2010 IOF Young Investigator Award Recipients at **IOF Regionals 1<sup>st</sup> Asia-Pacific Osteoporosis Meeting**, Singapore

- Shuli He *China*
- Manjula Hettiarachchi *Sri Lanka*
- Shigeyuki Muraki *Japan*
- Saroj K. Sahoo *India*
- Yuan-Yun Tseng *Taiwan, China*

# ANZBMS PAST AWARD RECIPIENTS

## ROGER MELICK YOUNG INVESTIGATOR AWARD

The Roger Melick Young Investigator Award is awarded to one of the eight Young Investigators that present in the Young Investigator Award Session. The prize is awarded according to their presentation and their handling of the questions and discussion. Eligibility criteria to apply for the Young Investigator Award are:

- The applicant must be a financial member of ANZBMS at the time of the application.
- The applicant must have made a substantial contribution to the work and be first and presenting author of the paper to be delivered at the ANZBMS Annual Scientific Meeting.
- The applicant must be currently undertaking work towards a higher degree (including FRACP).

1996	Vicky Kartsogiannis
1997	Linda Crofts
1998	Janelle Barry
1999	Liza-Jane Raggatt
2000	Sandra Iuliano-Burns ■ Nathan Pavlos
2001	David Good
2002	Kun Zhu
2003	Agatha Labrinidis ■ Xiaofang Wang
2004	Susan Allison ■ Kirk Ho Man Yip
2005	James Doecke
2006	Yosuke Kawasaki
2007	Stella Foley ■ Garry Williams
2008	Jonathan Gooi
2009	Nicola Lee
2010	Irene Zinonos

## CHRISTOPHER AND MARGIE NORDIN YOUNG INVESTIGATOR POSTER AWARD

1997	Anne Nelson ■ Hidenori Murata
1998	Marianne Holzherr
1999	Tanya Uebergang
2000	Josef Kaplan
2001	Rebecca Jackson
2002	Nathan Pavlos
2003	Nicole Walsh ■ Rouha Granfar
2004	Laura Gregory ■ Mark Bolland
2005	Mark Bolland ■ Catherine Wang
2006	Andrew Hattam ■ Estabelle Ang
2007	Taksum Cheng
2008	Hasnawati Saleh
2009	Ee-Cheng Khor
2010	Kylie Alexander

## CHRISTINE AND T. JACK MARTIN RESEARCH TRAVEL GRANT

2002	Catherine Middleton-Hardie
2003	Vicky Kartsogiannis
2004	Kerrie Sanders
2005	Susan Allison
2006	Mark Forwood
2007	Brya Matthews
2008	Roger Zebaze
2009	Bich Tran
2010	Garry Williams

## AMGEN/ANZBMS OUTSTANDING ABSTRACT AWARD

2003	Rob Will ■ Amanda Devine
2004	Roger Zebaze
2004	Christine Rodda
2005	Markus Seibel ■ Julian Quinn
2006	Yosuke Kawasaki ■ Julie Kuliwaba ■ Stella Foley ■ Dana Bliuc ■ Jonathan Gooi
2007	Colin Dunstan ■ Richard Prince ■ Maria Chiu ■ Natalie Sims ■ Paul Baldock ■ Ian Parkinson ■ Hong Zhou
2008	Robert Kalak, Andrew Grey
2009	Vicky Kartsogiannis, Nguyen Nguyen
2010	Markus Seibel ■ Emma Walker ■ Iris Wong ■ Sarah Brennan ■ Jasreen Kular ■ Hugh Zhang

## KAYE IBBERTSON AWARD ON METABOLIC BONE DISEASE

2005	Roger Zebaze
2006	Julie Pasco
2007	Tania Winzenberg
2008	Paul Baldock
2009	Mark Bolland
2010	Kun Zhu

## SOL POSEN RESEARCH AWARD

2006	Nathan Pavlos
2007	Aaron McDonald
2008	Haotian Feng
2009	Ming-Kang Chang
2010	Tak Sum Cheng



# JSBMR TRAVEL AWARD RECIPIENTS

- Tomohito Akiyama
- Atsushi Arai
- Tomoka Hasegawa
- Masahiro Hiasa
- Jun Hirose
- Yoko Hosaka
- Hiroko Hoshi
- Norihiro Ishida-Kitagawa
- Shozo Itoh
- Yuji Kasukawa
- Hiroshi Kobayashi
- Yuji Makino
- Hironari Masuda
- Kohji Miura
- Arei Miyamoto
- Daichi Morikawa
- Shigeyuki Muraki
- Hidetoshi Nojiri
- Yasuhisa Ohata
- Yoshitomo Saita
- Yuichiro Shimizu
- Masahiko Takahata
- Rikako Takashima
- Kenichiro Tanaka
- Toru Yago
- Masayo Yamagata
- Rika Yasuhara

# 21<sup>st</sup> IOF Advanced Training Course on Osteoporosis



Course Leader  
**Socrates E. Papapoulos**

31 January - 2 February 2012  
**InterContinental Hotel • GENEVA, SWITZERLAND**



# FINAL PROGRAMME

## SUNDAY SEPTEMBER 4, 2011

### 16:00-16:15 Official Opening

ARENA 1B

### 16:15-17:45 Osteoporosis in Oceania and the Asia-Pacific Region

ARENA 1B

**Co-chairs** John A. Kanis & Toshio Matsumoto

- 16:15 ■ Secular trends in fracture incidence: Why are fractures increasing in Asia but falling in the west?  
*Cyrus Cooper* abs#001
- 16:45 ■ Strategies to overcome epidemic of vitamin D deficiency in Asia  
*Ambrish Mithal* abs#002
- 17:15 ■ Strategies for preventing osteoporosis in Asia - Where do we go from here?  
*Edith Lau* abs#003

### 17:45-19:30 Welcome Reception & Opening of Exhibition

EXHIBITION HALL

## MONDAY SEPTEMBER 5, 2011

### 07:30-08:30 Breakfast Meeting

ARENA 1B

*The Meeting acknowledges the sponsorship of Novartis Pharmaceuticals*

### Efficacy and safety of long-term treatment with zoledronic acid 5 mg

*Erik Fink Eriksen*

### 07:30-08:30 Meet-the-Expert

ROOM 4

### Cancer and bone

*Toshiyuki Yoneda*

ROOM 5

### Economic evaluation of osteoporosis

*John A. Kanis*

*The Meeting acknowledges the sponsorship of Servier*

ROOM 6

### Vitamin D, common sense and the Goldilocks principle

*Neil Binkley*

ROOM 7

### Genetics in the dissection of bone biology

*Matthew Warman*

### 08:30-09:50 Osteoporosis in Men

ARENA 1B

**Co-chairs** Peter Ebeling & Rachel Davey

- 08:30 ■ Men, osteoporosis and body composition  
*Eric Orwoll* abs#004
- 09:05 ■ Osteoprotective actions of sex hormones mediate their nuclear receptors in bone cells  
*Shigeaki Kato* abs#005
- 09:35 ■ Androgens are critical to neuropeptide Y mediated control of bone formation  
*Ayse Zengin* abs#006

<b>09:50-10:20</b>	<b>Morning Tea</b>	
EXHIBITION HALL		
<b>10:20-12:00</b>	<b>Rheumatology and Bone</b>	
ARENA 1B	<i>Co-chairs</i> Stuart Ralston & Matt Brown	
10:20	<ul style="list-style-type: none"> <li>Osteoimmunology <i>Hiroshi Takayanagi</i></li> </ul>	abs#007
10:55	<ul style="list-style-type: none"> <li>Inflammation and bone resorption in rheumatoid arthritis <i>Steven Goldring</i></li> </ul>	abs#008
11:30	<ul style="list-style-type: none"> <li>Inflammation and bone formation in ankylosing spondylitis <i>Gethin Thomas</i></li> </ul>	abs#009
<b>10:20-12:00</b>	<b>IOF Young Investigator Session and Awards</b>	
ROOMS 5 & 6	<i>Co-chairs</i> Cyrus Cooper & Ambrish Mithal	
10:20	<ul style="list-style-type: none"> <li>Double stranded RNA increases bone mass in osteoporosis model mice by inhibiting osteoclastogenesis via interferon-<math>\beta</math>/STAT1 pathway <i>Arei Miyamoto</i></li> </ul>	abs#010
10:32	<ul style="list-style-type: none"> <li>Normative ultrasound data for population-based Australian men and women: The Geelong Osteoporosis Study <i>Haslinda Gould</i></li> </ul>	abs#011
10:44	<ul style="list-style-type: none"> <li>The transcription factor <i>Arid5b</i> modulates endochondral bone formation in cooperation with <i>Sox9</i> <i>Rikako Takashima</i></li> </ul>	abs#012
10:56	<ul style="list-style-type: none"> <li>The role of EPHB/EPHRINB molecules in fracture repair <i>Agnieszka Arthur</i></li> </ul>	abs#013
11:08	<ul style="list-style-type: none"> <li>Brown adipose tissue dysfunction causes bone loss <i>Masanobu Kawai</i></li> </ul>	abs#014
11:20	<ul style="list-style-type: none"> <li>A randomized controlled trial on safety and efficacy of single intramuscular vs staggered oral dose of 600,000 IU vitamin D in treatment of nutritional rickets <i>Krishanu Mondal</i></li> </ul>	abs#015
11:32	<ul style="list-style-type: none"> <li>Functional redundancy of GSK-3<math>\alpha</math> and GSK-3<math>\beta</math> to control chondrocyte differentiation through phosphorylation of RelA/NF-<math>\kappa</math>B p65 <i>Shozo Itoh</i></li> </ul>	abs#016
11:44	<ul style="list-style-type: none"> <li>Serum sclerostin level was positively correlated with bone mineral density in central south Chinese postmenopausal women <i>Zhifeng Sheng</i></li> </ul>	abs#017
<b>12:00-12:30</b>	<b>Lunch</b>	
EXHIBITION HALL		<i>The Meeting acknowledges the sponsorship of Servier</i>
<b>12:30-13:30</b>	<b>Satellite Symposium</b>	
ARENA 1B		
<b>13:30-14:30</b>	<b>Monday Poster Session</b>	
EXHIBITION HALL	<i>See Poster Listing. All odd numbered abstracts to be presented in this poster session.</i>	



## MONDAY SEPTEMBER 5, 2011 CONTINUED

### 14:30-16:00 Clinical Invited Abstracts - Therapeutics

ARENA 1B

**Co-chairs** Toshio Matsumoto & Philip Sambrook

- 14:30 ■ A randomized controlled trial of annual low dose zoledronate in postmenopausal women  
*Ian Reid* abs#018
- 14:45 ■ Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: Year 4 results  
*John Eisman* abs#019
- 15:00 ■ Parathyroid hormone 1-84 accelerates fracture healing in pubic bones of elderly osteoporotic women  
*Gerold Holzer* abs#020
- 15:15 ■ Denosumab decreases cortical porosity in postmenopausal women with low bone mineral density  
*Roger Zebaze* abs#021
- 15:30 ■ Long-term denosumab treatment in postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension  
*D. Thiebaud* abs#022
- 15:45 ■ Increased intracortical porosity is associated with higher serum undercarboxylated osteocalcin in middle-aged men  
*Itamar Levinger* abs#023

### 14:30-16:10 Workshop on Bone Regeneration

ROOMS 5 & 6

Presented with the Australian and New Zealand Orthopaedic Research Society

**Co-chairs** Aaron Schindeler & Christopher Vidal

- 14:30 ■ Lowering the efficacious dose of BMP-2 using heparan glycosaminoglycans  
*Simon Cool* abs#024
- 15:00 ■ Adipose stem cells and craniofacial regeneration  
*Yunfeng Lin* abs#025
- 15:30 ■ A basis for building bone: Novel biomaterials for new bone growth  
*Hala Zreiqat* abs#026
- 15:55 ■ The contribution of soft tissue osteoprogenitors to spinal fusion  
*Justin Bobyn* abs#027

### 16:00-16:30 Afternoon Tea

EXHIBITION HALL

### 16:30-17:30 Fracture Risk Algorithms: Soothsaying or Science?

ARENA 1B

**Co-chairs** Neil Binkley & Julie Pasco

- 16:30 ■ Getting to grips with FRAX®: How it really works  
*John A. Kanis* abs#028
- 17:05 ■ Effect of co-morbidities on fracture risk: Findings from the GLOW study  
*Elaine Dennison* abs#029
- 17:17 ■ Absolute fracture risk-based clinical threshold for Intervention: A decision curve analysis  
*Nguyen Nguyen* abs#030

## MONDAY SEPTEMBER 5, 2011 CONTINUED

### 16:30-17:30 Basic Abstracts - Connective Tissue

ROOMS 5 & 6

**Co-chairs** *Simon Cool & TBC*

- 16:30 ■ Transcriptional induction of ADAMTS5 by an NF- $\kappa$ B family member RelA/p65 in chondrocytes during osteoarthritis development  
*Hiroshi Kobayashi* abs#031
- 16:42 ■ Effects of monosodium urate (MSU) crystals on chondrocyte viability and function: Implications for development of joint damage in chronic gout  
*Ashika Chhana* abs#032
- 16:54 ■ The cross talks between Wnt/ $\beta$ -catenin and Rac-1 signaling in regulation of maintenance and function of superficial cell layer in articular cartilage  
*Rika Yasuhara* abs#033
- 17:06 ■ Inhibition of protein kinase-D promotes cartilage repair at injured growth plate in rats  
*Rosa Chung* abs#034
- 17:18 ■ Notch/Rbpj/Hes1 signal in chondrocytes modulates the terminal stage of endochondral ossification during skeletal growth and osteoarthritis development  
*Yoko Hosaka* abs#035

### 17:30-18:30

#### Satellite Symposium

ARENA 1B

*The Meeting acknowledges the sponsorship of MSD*

#### New Insights in Osteoporosis Management

### 18:30-19:30

#### Zumba Fitness Class

ROOM 5 & 6

## TUESDAY SEPTEMBER 6, 2011

### 07:30-08:30

#### Women in Bone Function

ARENA 1B

**Chair** *Rebecca Mason*

#### Does a successful career in science assume a choice between a research career and being a 'primary carer'?

*Ms Leneen Forde AC, Chancellor of Griffith University*

### 07:30-08:30

#### Meet-the-Expert

ROOM 4

#### The role of the vitamin D receptor in bone health

*Shigeaki Kato*

ROOM 5

#### Osteoporosis: When to measure, what to measure, whom to treat and with what?

*Stuart Ralston*

ROOM 6

#### Rheumatoid arthritis and bone

*Sakae Tanaka*

ROOM 7

#### Vertebral fracture: Definition, clinical impact and epidemiology considerations

*Cyrus Cooper*

*The Meeting acknowledges the sponsorship of Eli Lilly*

## TUESDAY SEPTEMBER 6, 2011 CONTINUED

### 08:30-09:50 **The Effects of Ageing**

ARENA 1B

**Co-chairs** *Eric Orwoll & Gustavo Duque*

- 08:30     ▪ Sarcopenia, ageing and sarco-osteoporosis  
*Neil Binkley* abs#036
- 09:05     ▪ Sarcopaenia and vitamin D  
*David Scott* abs#037
- 09:25     ▪ Prevalence of sarcopenia in older women: The Geelong Osteoporosis Study  
*Julie Pasco* abs#038
- 09:37     ▪ Role of Tmem119 in the muscle ossification signaling  
*Kenichiro Tanaka* abs#039

### 09:50-10:15 **Morning Tea**

EXHIBITION HALL

*The Meeting acknowledges the sponsorship of Eli Lilly*

### 10:15-12:00 **Non-Canonical Bone**

ARENA 1B

**Co-chairs** *Alvin Ng & Emma Duncan*

- 10:15     ▪ Non canonical bone: Bone fat brain  
*Paul Baldock* abs#040
- 10:45     ▪ Bones and salt: The renin-angiotensin-aldosterone axis in bone  
*Caryl Nowson* abs#041
- 11:15     ▪ LRP5, serotonin and bone  
*Matthew Warman* abs#042
- 11:45     ▪ The role of osteocalcin in glucocorticoid-induced metabolic dysfunction  
*Tara Brennan-Speranza* abs#043

### 10:15-12:00 **Malignancy and Bone**

ROOMS 5 & 6

**Co-chairs** *David Thomas & Toshio Matsumoto*

- 10:15     ▪ Pathophysiology of bone disease in multiple myeloma  
*Andrew Zannettino* abs#044
- 10:45     ▪ Mechanisms and prevention for cancer chemotherapy-induced bone defects  
*Cory Xian* abs#045
- 11:15     ▪ Bone pain associated with cancer metastasis to bone  
*Toshiyuki Yoneda* abs#046
- 11:45     ▪ Treatment with interleukin 6 receptor antibodies inhibits prostate cancer growth in a murine model of bone metastasis  
*Dennis Basel* abs#047

### 12:00-12:30 **Lunch**

EXHIBITION HALL

### 12:35-13:35 **Satellite Symposium**

ARENA 1B

*The Meeting acknowledges the sponsorship of Amgen in association with GlaxoSmithKline Australia*

#### **Denosumab: new data, novel perspectives on anti-fracture effects**

**Chair** *John Eisman*

- Denosumab: targeting treatment to the causes of bone fragility  
*Ego Seeman*
- Long-term efficacy and safety across a spectrum of patients  
*Charles Inderjeeth*

## TUESDAY SEPTEMBER 6, 2011 CONTINUED

### 13:35-14:30 Tuesday Poster Session

EXHIBITION HALL *See Poster Listing. All even numbered abstracts to be presented in this poster session.*

### 14:30-16:10 Clinical Management of Osteoporosis I

ARENA 1B **Co-chairs** Edith Lau & Rory Clifton-Bligh

- 14:30 ■ To BMD or not to BMD?  
*John A. Kanis* abs#048
- 15:00 ■ The role of fracture liaison services in the management of patients with osteoporosis  
*Markus Seibel* abs#049
- 15:25 ■ Incidence and prevention of second hip fracture in Japan  
*Hiroshi Hagino* abs#050
- 15:55 ■ Timing of adverse outcomes following osteoporotic fractures in elderly women and men: Implication for long term management  
*Dana Bliuc* abs#051

### 14:30-16:00 Basic Abstracts

ROOMS 5 & 6 **Co-chairs** Nao Takahashi and Natalie Sims

- 14:30 ■ Altered osteocyte function in osteoarthritis: A possible pathological role in subchondral bone sclerosis  
*Yin Xiao* abs#052
- 14:45 ■ A gain-of-function type mutation of the natriuretic peptide receptor B causes acceleration of skeletal growth and osteoporotic change in humans and mice  
*Kohji Miura* abs#053
- 15:00 ■ Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression  
*Masahiro Hiasa* abs#054
- 15:15 ■ Inhibition of retinoic acid receptor (RAR) signalling potentiates osteoblast differentiation and bone formation  
*Alanna Green* abs#055
- 15:30 ■ B cells do not influence intramembranous bone modelling in vivo  
*Allison Pettit* abs#056
- 15:45 ■ Selective serotonin re-uptake inhibitors (SSRIs) inhibit human osteoclast and osteoblast formation and function  
*Jason Hodge* abs#057

### 16:00-16:30 Afternoon Tea

EXHIBITION HALL

### 16:30-17:30 ANZBMS Annual General Meeting

ARENA 1B

## TUESDAY SEPTEMBER 6, 2011 CONTINUED

**17:30-18:30**

ARENA 1B

### New Investigator Session

**Co-chairs** *Andy Wu & Tara Brennan-Spinoza*

- 17:30     ■ c-Fos plays an essential role in up-regulation of RANK expression in osteoclast precursors  
*Atsushi Arai* abs#058
- 17:35     ■ Oncostatin M potently induces IL-6 and RANKL expression in mouse synovial fibroblasts and synergises with IL-1  
*Nicole Walsh* abs#059
- 17:40     ■ Epigenetic regulation of osteoclast differentiation: Possible involvement of Jmjd3 in the histone demethylation of Nfatc1  
*Jun Hirose* abs#060
- 17:45     ■ Targeted disruption of the glucocorticoid receptor in adipocytes results in, an osteosclerotic phenotype, increased fat mass and growth retardation in mice  
*Yaqing Zhang* abs#061
- 17:50     ■ Analysis of the roles of FGF23 in fetus-specific mineral metabolism using Hyp mouse  
*Yasuhisa Ohata* abs#062
- 17:55     ■ A computational approach to understanding functional behaviour of bone multicellular units  
*Pascal Buenzli* abs#063

**Co-chairs** *Ashika Chhana & Desa Walsh*

- 18:00     ■ Viscoelastic response of PTH, ibandronate and combination treatment in ovariectomized rat femur correlating with BMD  
*Xiao Yang* abs#064
- 18:05     ■ Whole vertebral body strength predicted by bone mineral density from DXA and by bone microarchitecture from micro-CT  
*Egon Perilli* abs#065
- 18:10     ■ Biomaterial scaffolds for musculoskeletal regenerative medicine: An in vitro analysis  
*David Musson* abs#066
- 18:15     ■ Novel loci associated with bone mineral density: Results of a multipoint linkage analysis of extended pedigrees  
*Sing Nguyen* abs#067
- 18:20     ■ Glucocorticoid therapy deteriorates bone strength but increases post-yield energy to fracture by the reduction of degree of mineralization of bone in a mice model of rheumatoid  
*Masahiko Takahata* abs#068
- 18:25     ■ Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor Saliphenylhalamide (SaliPhe) through inhibition of osteoclast maturation and bone resorption  
*An Qin* abs#069

**18:30-19:30**

ARENA 1B

### Satellite Symposium

*The Meeting acknowledges the sponsorship of Novartis Pharmaceuticals*

#### Presentation of the efficacy and safety of long-term treatment with zoledronic acid 5 mg

*Erik Fink Eriksen*

**19:30-22:00**

KURRAWA SURF  
LIFE SAVING CLUB

### Young Investigator BBQ Buffet



## WEDNESDAY SEPTEMBER 7, 2011

### 07:30-08:30 Student - Mentor Breakfast - Building a Career in Skeletal Research: From Foundations to Penthouse Suite

ARENA 1B

Presentations by Allison Pettit & Matthew Gillespie

### 07:30-08:30 Meet-the-Expert

ROOM 4

#### Bone and cartilage pathophysiology in osteoarthritis: Therapeutic implications

Steve Goldring

ROOM 5

#### Sex steroids and bone in men: What to measure, what to treat?

Eric Orwoll

ROOM 6

#### How does adipose tissue affect the skeleton? Laboratory studies

Jillian Cornish

ROOM 7

#### Vitamin D derivatives

Toshio Matsumoto

### 08:30-09:50 Paget's Disease

ARENA 1B

Co-chairs Neil Binkley & Ian Reid

- 08:30 ■ The epidemiology of Paget's disease  
Tim Cundy abs#070
- 09:00 ■ Genetics of Paget's disease of bone  
Stuart Ralston abs#071
- 09:35 ■ Paget's disease of bone-associated Sequestosome 1/p62 mutant proteins increase RANKL-induced AP-1 signalling and affect cellular co-localisation with key signalling intermediates Ajuba and TRAF6  
Sarah Rea abs#072

### 09:50-10:15 Morning Tea

EXHIBITION HALL

### 10:15-12:00 Biomechanics and Bone Measurement

ARENA 1B

Co-chairs Satoshi Mori & Belinda Beck

- 10:15 ■ Why bones fail: Structure and mechanics  
Mark Forwood abs#073
- 10:45 ■ Quantifying the material composition and structure of bone non-invasively  
Ego Seeman abs#074
- 11:15 ■ Osteocytes and calcium: A little bit of give and take  
David Findlay abs#075
- 11:45 ■ Analysis of oxidative stress and antioxidant enzymes in mechanical stress response  
Daichi Morikawa abs#076

### 10:15-12:00 Skeletal Dysplasias

ROOMS 5 & 6

Co-chairs Keiichi Ozono & Emma Duncan

- 10:15 ■ Skeletal dysplasias: A new approach  
Andreas Zankl abs#077
- 10:40 ■ Hypophosphataemia and FGF23  
Seiji Fukumoto abs#078
- 11:15 ■ Mouse models for skeletal dysplasias  
Matthew Warman abs#079
- 11:40 ■ Variable osteogenesis imperfecta phenotype resulting from a founder FKBP10 mutation in Samoa  
Tim Cundy abs#080

## WEDNESDAY SEPTEMBER 7, 2011 CONTINUED

### 12:00-13:00 Lunch

EXHIBITION HALL

### 12:00-13:00 New Investigator Oral Poster Session

EXHIBITION HALL

### 13:00-14:00 Satellite Symposium

ARENA 1B

### 14:00-15:50 Therapeutics in Osteoporosis: Controversies

ARENA 1B

**Co-chairs** John Eisman & Graeme Jones

- 14:00 ■ Bisphosphonates: The good, the bad and the ugly  
*Peter Ebeling* abs#081
- 14:30 ■ Fracture healing -Mechanical and histological changes with bisphosphonate treatment  
*Satoshi Mori* abs#082
- 15:00 ■ Atypical subtrochanteric and diaphyseal femoral fractures - What we know and what we don't  
*Alvin Ng* abs#083
- 15:25 ■ Adverse cardiovascular effects of calcium supplements may not persist after discontinuation of supplements: 5-year follow up of the Auckland Calcium Study  
*Loretta Wigg* abs#084
- 15:37 ■ Does calcium supplementation with and without vitamin D increase cardiovascular risk? A clinico-Bayesian interpretation  
*Thach Thach* abs#085

### 14:00-15:40 Osteoclasts

ROOMS 5 & 6

**Co-chairs** Hiroshi Takayanagi & Gerald Atkins

- 14:00 ■ Quiescent osteoclast precursors  
*Naoyuki Takahashi* abs#086
- 14:25 ■ Epigenetic regulation of osteoclast differentiation  
*Sakae Tanaka* abs#087
- 14:50 ■ Osteoblastic support of osteoclasts: The role of gp130 signalling  
*Natalie Sims* abs#088
- 15:15 ■ An osteoclast-derived coupling factor  
*Sunao Takeshita* abs#089

### 15:45-16:15 Afternoon Tea

EXHIBITION HALL

## WEDNESDAY SEPTEMBER 7, 2011 CONTINUED

### 16:15-17:55 ANZBMS Young Investigator Session

ARENA 1B

*Co-chairs* Stuart Ralston & Steven Goldring

- 16:15 ■ Prevention of skeletal damages with folic acid supplementation in young rats receiving long-term methotrexate chemotherapy  
*Chiaming Fan* abs#090
- 16:27 ■ Methotrexate chemotherapy-induced bone loss and marrow adiposity is associated with deregulation of the Wnt/ $\beta$ -catenin signalling pathway  
*Kristen Georgiou* abs#091
- 16:39 ■ The vitamin D receptor promotes human prostate cancer cell growth via a ligand Independent Pathway  
*Yu Zheng* abs#092
- 16:51 ■ How well do the FRAX<sup>®</sup> (AUS) and Garvan calculators predict fractures from the Geelong Osteoporosis Study (GOS)  
*Yu Zhang* abs#093
- 17:03 ■ Fragility fracture and osteoarthritis: Interactions between bone mineral and bone mass index  
*Mei Chan* abs#094
- 17:15 ■ Endogenous parathyroid hormone is associated with reduced cartilage volume in vivo in a population-based sample of adult women  
*Sharon Brennan* abs#095
- 17:27 ■ Fat mass and fracture risk in elderly men and women: A prospective study  
*Shuman Yang* abs#096
- 17:39 ■ Sclerostin induces osteocyte support of osteoclast formation and osteoclast activity  
*Asiri Wijenayaka* abs#097

### 16:15-17:45 Clinical Abstracts - Bone Nutrition

ROOMS 5 & 6

*Co-chairs* Paul Anderson & TBC

- 16:15 ■ Lower serum 25-hydroxyvitamin D levels are associated with greater all-cause and cancer-related mortality among Australian adults: Findings from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab)  
*Robin Daly* abs#098
- 16:30 ■ Vitamin D insufficiency in older women: prevalence and impact on bone density, fracture risk and mortality  
*Kun Zhu* abs#099
- 16:45 ■ Serum 25-hydroxy vitamin D (25OHD) and incident or worsening knee pain in older adults: A five-year longitudinal study  
*Laura Laslett* abs#100
- 17:00 ■ Annual high-dose oral vitamin D3: Is the increased risk of falls attributable to changes in muscle strength?  
*Kerrie Sanders* abs#101
- 17:15 ■ Maternal vitamin D supplementation during pregnancy prevents vitamin D deficiency in the newborn. A randomised controlled trial  
*Christine Rodda* abs#102
- 17:30 ■ Treatment with oral cholecalciferol 2000 IU and 5000 IU on serum vitamin D, PTH, bone turnover and muscle strength in patients with vitamin D deficiency  
*Terrence Diamond* abs#103

### 16:30-18:00 IOF Regional Advisory Council Meeting *invitation only*

ROOM 7

### 19:30-23:00 Gala Dinner

ARENA 2

*This is a ticketed function*

## THURSDAY SEPTEMBER 8, 2011

### 07:00-08:15 Beach Breakfast

KURRAWA SURF  
LIFE SAVING CLUB

### 09:00-10:45 Paediatric Bone Disease

ARENA 1B

**Co-chairs** *Ambrish Mithal & TBC*

- 09:00 ■ Measuring a growing skeleton, and the effect of ethnicity on bone and body composition  
*Christopher Cowell* abs#104
- 09:30 ■ Nutrition and children's bone  
*Tania Winzenberg* abs#105
- 09:50 ■ Osteoporosis and osteopetrosis in the young  
*Keiichi Ozono* abs#106
- 10:20 ■ Growth from birth to adulthood and bone mineral density data from the New Delhi Birth Cohort  
*Nikhil Tandon* abs#107
- 10:32 ■ Longitudinal change of bone geometry in the mid femur of growing children  
*Pascale Bridge* abs#108

### 09:00-10:45 Final Oral Abstracts

ROOM 5

**Co-chairs** *Geoff Nicholson & TBC*

- 09:00 ■ The role of osteocytes in the skeletal pathology of neurofibromatosis type I (NF1)  
*Mateusz Kolanczyk* abs#109
- 09:12 ■ Muscle-specific knockout of Nf1 causes neonatal lethality  
*Kate Sullivan* abs#110
- 09:24 ■ RAP-011 augments callus formation in closed rat fractures  
*Alyson Morse* abs#111
- 09:36 ■ A Genome-wide association study of bone mineral density: Results from the Odense Androgen Study  
*Claus Brasen* abs#112
- 09:48 ■ Fractures and falls with chronic antiepileptic drug use and patient awareness of the issue  
*Baemisla Shiek Ahmad* abs#113
- 10:00 ■ Serum uric acid is associated with bone loss and body composition in women: A longitudinal study  
*Joanna Makovey* abs#114
- 10:12 ■ Safety and efficacy of denosumab in giant cell tumour of bone (GCTB)  
*David Thomas* abs#115
- 10:24 ■ Parathyroid hormone excess and deficiency: Is Peter really robbed or Paul paid?  
*Thuy Vu* abs#116

### 10:45-11:15 Morning Tea

FOYERS A & B

### 11:15-12:45 Clinical Osteoporosis Management II

ARENA 1B

**Co-chairs** *Peter Ebeling & John A. Kanis*

- 11:15 ■ New strategies for treatment of osteoporosis  
*Toshio Matsumoto* abs#117
- 11:45 ■ Osteoporosis management and mortality  
*Jackie Center* abs#118
- 12:15 ■ Osteoporosis: The future  
*John Eisman* abs#119

### 12:45-13:15 Close and Awards

ARENA 1B



# IOF Regionals KUALA LUMPUR 12

3<sup>rd</sup> Asia-Pacific Osteoporosis Meeting

KUALA LUMPUR CONVENTION CENTRE 14-17 DECEMBER 2012





# POSTER LISTING

Presenting authors should be present at their posters during 13:30 to 14:30 according to the following schedule:

Poster number	Poster presentation date
Odd	Monday September 5
Even	Tuesday September 6

## BASIC BONE RESEARCH Other

- ABS#201 Vimesh Avlani**  
Control of intracellular cAMP levels by calcium-sensing receptor agonists and modulators: Roles of Gi/o and phosphodiesterases
- ABS#202 Ebrahim Bani Hassan**  
Focal subchondral bone attrition of the distal metacarpal condyles in Thoroughbred racehorses is associated with microfracture accumulation and increased bone volume fraction of surrounding bone
- ABS#203 Xiaoxiao Cai**  
Adipose stem cells originate from pericytes which contribute to vascularization
- ABS#204 Baosheng Guo**  
Highly expressed CKIP-1 and lowly expressed Smad1/5 in aged callus specimen
- ABS#205 Mateusz Kolanczyk**  
Neurofibromin (Nf1) is required for normal skeletal muscle development
- ABS#206 Hidetoshi Nojiri**  
Cytoplasmic superoxide causes bone fragility due to low turnover osteoporosis and impaired collagen cross-linking
- ABS#207 Nurdiana Nurdiana**  
Effect of genistein on osteoblast and osteoclast number in hypoestrogenic rat
- ABS#208 Divya Singh**  
Daidzein prevents the increase in CD4+CD28null T Cells in ovariectomized mice: A key mechanism for anti-osteoclastogenic effect
- ABS#209 Divya Singh**  
Supplementation of acetone soluble fraction of Butea monosperma crude extract to growing rats provides greater protection against bone loss after ovariectomy

- ABS#210 Jennifer Tickner**  
Choline kinase beta is an important regulator of bone homeostasis
- ABS#211 Hulya Uzkeser**  
X-ray radiography, MRI and multidetector CT of Spine
- ABS#212 Maureen Watson**  
The effects of anti-psychotic medications on BMD and bone microarchitecture in rats fed high-fat diet
- ABS#213 Toru Yago**  
Memantine potently inhibits human osteoclastogenesis

## BONE BIOMECHANICS AND QUALITY

Including Bone Structure, Mechanical Properties and Bone Measurement Including DXA

- ABS#214 Maria Alonso**  
Assessment of panoramic radiomorphometric indices in a large mixed Brazilian population
- ABS#215 Pascale Bridge**  
Validation of longitudinal DXA changes in body composition from pre-to mid-adolescence using MRI as reference
- ABS#216 Mei Chan**  
Quantitative ultrasound and fracture prediction in non-osteoporotic men and women
- ABS#217 Ali Ghasem-Zadeh**  
Is aBMD a predictor of microarchitecture?
- ABS#218 Zohreh Hamidi**  
Defining cut-off values for the diagnosis of osteoporosis in postmenopausal women using the DXL method
- ABS#219 Tomoka Hasegawa**  
Ultrastructural assessment for vascular calcification in the aorta of klotho-/- mice

## BONE BIOMECHANICS AND QUALITY

Including Bone Structure, Mechanical Properties and Bone Measurement Including DXA

**ABS#220** **Jacqueline Hislop-Jambrich**  
Effective dose and QCT of the proximal femora: What are the facts?

**ABS#221** **Jonathan Kaufman**  
A new stochastic model for hip fracture risk

**ABS#222** **Kamarul Ariffin Khalid**  
Response to loading in ex vivo bovine bone

**ABS#223** **Raman Marwaha**  
Prevalence of morphometric vertebral fractures using an advanced semi-automated method in healthy Indians

**ABS#224** **Khadijeh Mirzaei**  
Is difference between the effects of body mass index and body fat distribution on bone mineral density?

**ABS#225** **Soma Mitra**  
Association between bone mineral density, lean mass and fat mass in British African men, women and children living in London, U.K.

**ABS#226** **Huynh Nguyen**  
Radiation sterilization reduces the energy absorption capacity of morsellized cancellous bone allografts during compaction

**ABS#227** **Zairin Noor**  
Bone strength and atomic mineral characters in osteoporosis

**ABS#228** **Roger Price**  
A phantom for determining accuracy of DXA-derived femoral neck structural geometry

**ABS#229** **Richard Prince**  
Differences in structural geometrical outcomes at the neck of the proximal femur using two-dimensional DXA-derived projection (APEX) and three-dimensional QCT-derived (BIT QCT) techniques

**ABS#230** **Richard Prince**  
QCT and DXA hip size and strength measurements are highly correlated

**ABS#231** **Mohammad Salamat**  
Assessment of absorbed dose in postmenopausal women, using DXA, and its relationship with height, weight and body mass index

**ABS#232** **Phil Salmon**  
Epiphyseal trabecular bone mineral density could provide a murine ovariectomy model of pre-osteoarthritis pathology

**ABS#233** **Ewa Spiesz**  
Experimental validation of a multiscale model of mineralized collagen fibers at two levels of hierarchy

**ABS#234** **Nikhil Tandon**  
Correlation between BMD measured by peripheral and central DXA in healthy Indian children and adolescents aged 10 -18 years

**ABS#235** **Xiao-Fang Wang**  
Racial difference in bone microstructure and density at distal radius and tibia between young Chinese and Caucasian men

**ABS#236** **Lana Williams**  
Quantitative heel ultrasound (QUS) as a measure of bone quality among men and women with depression: Geelong Osteoporosis Study (GOS)

**ABS#237** **Mohammad Zarrinkalam**  
The histomorphometric and compositional characteristics of bone in an osteoporotic sheep model

## BONE, CARTILAGE AND CONNECTIVE TISSUE MATRIX

**ABS#238** **Tomohito Akiyama**  
Enhancement of inflammatory osteoclastogenesis by lysine-specific gingipain

**ABS#239** **Monica Cirstoiu**  
Resurfacing arthroplasty in osteoporosis hip osteoarthritis

**ABS#240** **Tomoka Hasegawa**  
Endochondral ossification in mice over-expressing tissue non-specific alkaline phosphatase driven by type II collagen promoter

## BONE, CARTILAGE AND CONNECTIVE TISSUE MATRIX

**ABS#241 Ian Parkinson**  
Alendronate treatment reduces tibial subchondral bone damage in early-stage osteoarthritis: An in vivo micro-CT study in a rodent model

**ABS#242 Aaron Schindeler**  
A novel mouse model of tibial pseudarthrosis featuring localized double inactivation of the Nf1 gene

**ABS#243 Yuichiro Shimizu**  
Evaluation of a new automated chemiluminescence immunoassay for FGF23

**ABS#244 Jinwen Tu**  
Transgenic disruption of glucocorticoid signaling in osteoblasts attenuates inflammation and bone loss in collagen antibody-induced arthritis

## BONE-REGULATING HORMONES

Including Vitamin D, Sex Steroids, Phosphatonins, Calcitonin, PTH

**ABS#245 Nasser Al-Daghri**  
Modest reversal of metabolic syndrome manifestations with vitamin D correction: A 12-month prospective study

**ABS#246 Decio Armanini**  
Vitamin D in polycystic ovary syndrome

**ABS#247 Beena Bansal**  
Effect of cholecalciferol supplementation in hemodialysis patients

**ABS#248 Rachel Davey**  
Identification of target genes in mineralising osteoblasts that are directly regulated via the androgen receptor

**ABS#249 Christopher-John Farrell**  
State of the art of vitamin D assays: Latest generation assays

**ABS#250 Flavia Fayet**  
Vitamin D insufficiency in healthy Australian office workers

**ABS#251 Mukul Gupta**  
High prevalence of vitamin D deficiency in Asian-Indian patients with fragility hip fracture

**ABS#252 Kiok Han**  
Association study of plasma serotonin levels with bone turnover status before and after hormone therapy in post-menopausal women

**ABS#253 Nobuaki Ito**  
Phosphate 'sensing' by human bone

**ABS#254 Sandra Iuliano-Burns**  
Sarcopenia and vitamin D deficiency are risk factors for falls but remain undetected in aged care residents

**ABS#255 Masakazu Kogawa**  
25(OH)-vitamin D3 acts directly on osteoclasts to reduce resorption: What is the mechanism?

**ABS#256 Fatemeh Larijani**  
The association between vitamin D serum levels and blood pressure status: An Iranian study

**ABS#257 Jenson Mak**  
Improving mobility and reducing disability in older people through early high-dose vitamin D replacement following hip fracture (the REVITAHIP trial): Preliminary results

**ABS#258 Ambrish Mithal**  
Widespread vitamin D deficiency among Indian health professionals

**ABS#259 Ambrish Mithal**  
Effect of oral versus intramuscular vitamin D replacement in healthy Indians adults

**ABS#260 Vladyslav Povoroznyuk**  
Vitamin D- Deficiency and insufficiency in people of regions of Ukraine

**ABS#261 Kerrie Sanders**  
Annual high-dose oral vitamin D3: Is increased risk of fractures attributable to changes in bone turnover markers?

**ABS#262 Thach Tran**  
Serum testosterone and fracture risk in men: A comparison of radioimmunoassay versus liquid chromatography tandem mass spectrometry

**ABS#263 Ritu Trivedi**  
Age and skeletal site affect responsiveness of bone marrow stromal cells from different trabecular compartments in different physiological conditions: Effect of estrogen and vitamin D

**ABS#264 Andrew Turner**  
Increased bone volume in the bone-specific CYP27b1 transgenic mouse

**ABS#265 Hulya Uzkeser**  
Vitamin D levels in subjects with type 2 diabetes mellitus

**ABS#266 Subhash Wangnoo**  
Osteoporosis, osteopenia and 25-hydroxy-vitamin D levels in patients after renal transplantation

**ABS#267 WeiBo Xia**  
Vitamin D 1 $\alpha$ -hydroxylase gene mutations in Chinese patients with pseudo-vitamin D-deficiency ricket

## BONE-REGULATING HORMONES

Including Vitamin D, Sex Steroids, Phosphatonins, Calcitonin, PTH

**ABS#268 Dongqing Yang**  
The role of vitamin D in the proliferation and differentiation of osteoblasts in vitro

**ABS#269 Noriko Yoshimura**  
Vitamin D insufficiency and deficiency as a risk factor for fast bone loss among elderly men and women: The ROAD Study

**ABS#270 Roger Zebaze**  
Insights into the effects of parathyroid hormone treatment on bone structure

**ABS#271 HM Zhu**  
Vitamin D status in healthy man and woman

## CANCER AND BONE

**ABS#272 Estabelle Ang**  
Paclitaxel inhibits osteoclast formation and bone resorption via influencing widespread cytoskeletal aberrations, mitotic cycle arrest and RANKL-induced activation of NF- $\kappa$ B and ERK

**ABS#273 Emma Baker**  
Epigenetic signatures of osteosarcoma

**ABS#274 Liliana Endo-Munoz**  
Regulation of osteoclast differentiation by metastatic osteosarcoma

**ABS#275 Patricia Ho**  
Blockade of PTH/PTHrP signaling inhibits invasive capacity of genetically engineered mouse osteosarcoma in vitro

**ABS#276 Tristan King**  
Increased Pro-inflammatory cytokine expression and NF- $\kappa$ B activation potentiate osteoclast formation following methotrexate treatment

**ABS#277 Laura Laslett**  
Zoledronic acid reduces bone marrow lesions and knee pain over one year

**ABS#278 Patsie Polly**  
Musculoskeletal breakdown due to cancer cachexia: Molecular and morphological effects

**ABS#279 Julie Quach**  
Single cytotoxic agents directly cause bone loss due to increased osteoclastogenesis: Implications for preventing bone loss in cancer patients

**ABS#280 Cristina Vincent**  
Methotrexate treatment results in loss of dendritic morphology and differential gene expression in osteocyte-like MLO-Y4 cells

**ABS#281 Masayo Yamagata**  
Attenuated megalin expression in hyperfunctioning parathyroid tumors

**ABS#282 Yu Zheng**  
The vitamin D receptor has a ligand-independent role in human breast cancer cell growth

**ABS#283 Yu Zheng**  
Interleukin 6 modulates tumour behavior in bone via a RANKL dependent pathway

## CELL BIOLOGY IN BONE

Including Osteoblasts, Osteoclasts and Osteocytes

**ABS#284 Izaak Akbar**  
Effect of Methyl Glyoxal Exposure on Hydrogen Peroxide Level in Pre-Osteoblast MC3T3E1 Cell Line

**ABS#285 Usha Bava**  
Differences in in vitro proliferation rates of osteoblasts from Polynesian and European patients

**ABS#286 Qin Bian**  
Protective effect of oleanolic acid on bone mesenchymal stem cells in OVX-induced rats by stem cell microarray

**ABS#287 Katharina Blankenstein**  
The negative effects of glucocorticoids on bone are primarily mediated by genes involved in osteoblast differentiation and bone remodeling

**ABS#288 Jun Chen**  
Function and regulation of epithelial sodium channels (ENaC) in osteoblasts

**ABS#289 Ruei-Ming Chen**  
MicroRNA-1 mediates oxidative stress-induced apoptotic insults to osteoblasts

**ABS#290 Tak Cheng**  
Versatile roles of V-ATPase Accessory subunit Ac45 in osteoclast formation and function

**ABS#291 Jessica Costa**  
Long-chain saturated fatty acids promote the differentiation of cells of the marrow stromal line Kusa4b10 into adipocytes

**ABS#292 Tania Crotti**  
Inhibition of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage human osteoclast differentiation

**ABS#293 Anak Dharmapatni**  
Regulation of human osteoclast activity and apoptosis by IAP inhibitors in vitro

## CELL BIOLOGY IN BONE

Including Osteoblasts, Osteoclasts and Osteocytes

ABS#294

**Anak Dharmapatni**

Increased SOFAT mRNA expression during osteoclast development, evidence that SOFAT is not only associated with T cells

ABS#295

**Tania Fernandes**

Human adipose tissue is a better source of mesenchymal stem cells for osteogenic differentiation than umbilical cord tissue

ABS#296

**Patricia Ho**

Inhibiting ephrinB2/EphB4 binding prevents progression of osteoblast differentiation and enhances osteoclastogenic factors

ABS#297

**Hiroko Hoshi**

Mutation of Aldh2 gene suppresses osteoblasts differentiation by accumulation of acetaldehyde and peroxidated lipid-protein

ABS#298

**Norihiro Ishida-Kitagawa**

Identification of a novel partner of DAP12 in the regulation of actin-ring formation in osteoclasts

ABS#299

**Peng Jia**

Iron overload could enhance the osteoclast differentiation and activity both in vitro and in vivo through the production of reactive oxygen species

ABS#300

**Chi Teng Lei**

UMR-106 osteoblast cells express components of the renin-angiotensin system and are regulated by glucocorticoids

ABS#301

**GuangFei Li**

Influence of hepcidin on intracellular calcium of human osteoblasts

ABS#302

**Huaqing Liu**

Dose-dependent effects of selenium on the differentiation of osteoclasts in vitro

ABS#303

**Hironari Masuda**

Anti-apoptotic Bcl-2 family member Mcl-1 positively regulates cell viability and negatively regulates bone-resorbing activity of osteoclasts

ABS#304

**Nathan Pavlos**

Functional analysis of the microtubule-binding dynein-dynactin complex in osteoclasts

ABS#305

**Mark Rybchyn**

The mammalian target of rapamycin complexes 1 and 2 mediate responses to strontium ranelate in primary human osteoblasts

ABS#306

**Preetinder Singh**

Measurement of induced membrane-bound RANKL activity in stimulated osteoblastic cells

ABS#307

**Stephen Tonna**

EphrinB2 signalling in osteoblasts is required for normal osteoblast differentiation and osteoclast maturation

ABS#308

**Amanda van der Kraan**

Hsp90 inhibitors enhance osteoclast formation in vitro in a NFATc1 independent manner through the induction of stress responses

ABS#309

**Katie Welldon**

Calcium as an anabolic stimulus of osteoblast differentiation to an osteocyte-like phenotype

ABS#310

**Ming Zheng**

Identification of synthetic V-ATPases inhibitors selective for osteoclast proton pump

## CLINICAL BONE DISEASE Other

ABS#311

**Mohammed Ali**

Yakub-Sarwar's method of laser osteoperforation: A minimal invasive modality for treatment of a vascular necrosis (Avn) of femoral head. A preliminary report

ABS#312

**Kalliopi Alpantaki**

Changes of blood gases and hemodynamic parameters in patients undergoing vertebral balloon kyphoplasty in multiple levels

ABS#313

**Seng Bin Ang**

Two-year experience of intravenous zoledronic acid in a women's hospital

ABS#314

**Melissa Cantley**

Inhibiting histone deacetylases expressed in human periodontal tissues prevents bone loss in an animal model of periodontal disease

ABS#315

**Catalin Cirstoiu**

Strontium ranelat in male osteoporosis- Personal experience

ABS#316

**Bharat Dave**

Percutaneous vertebroplasty: Is it a cake walk? Lessons learnt

ABS#317

**Peter Ebeling**

Lower Fat Mass and Lower Bone Formation Predict Greater Bone Loss with Tenofovir in HIV-infected Adults

ABS#318

**David Findlay**

The Natural History of Periacetabular Osteolytic Lesions

ABS#319

**Mai Ghabashei**

Health knowledge and dietary intake risk factors leading to osteopenia and osteoporosis in university students.

*By: Mai Adel Mohammed Nour Ghabashei, Faten Ibrahim Saleh Al-Homyani, Manal Mansour Hassan Hemeish, Rehab Yousif Abdullah Al-Ghamdi, Shym*



## CLINICAL BONE DISEASE Other

**ABS#320 Manak Gupta**  
Evaluation of beta tricalcium phosphate in human infrabony periodontal osseous defects: A clinical study

**ABS#321 Hiroshi Hagino**  
FOQUS Study (Study on Factors for Osteoporosis Quality-Of-life in Japanese Subjects) - Interim report

**ABS#322 Kyung-Hoe Huh**  
Influence of BMI on bone structure at the weight-bearing and non-weight-bearing skeletal regions in premenopausal women

**ABS#323 Pulkit Kinra**  
Evaluation of the relative efficacy of an allograft used alone and that in combination with simvastatin in the treatment of human periodontal infrabony defects – A clinical and radiological study

**ABS#324 Evgenia Kocheikova**  
Vascular endothelial growth factor: Association with bone loss in COPD patients

**ABS#326 Marlena Kruger**  
Bone mineral density, quantitative ultrasound measurement and calcium intake among postmenopausal Chinese women

**ABS#327 Shailendra Lakhota**  
Patient characteristics and risk factors of osteoporosis in urban Indian patients attending an orthopedic clinic for back pain

**ABS#328 Yuji Makino**  
Analysis of axial skeleton development in Type 2 Spondylocostal Dysostosis model Mesp2(-/-) mouse, suggesting an essential role of the segmentation clock output for proper alternate arrangement of vertebral bodies and intervertebral discs

**ABS#329 Usman Malabu**  
Calciophylaxis in Northern Australia: An emerging concept

**ABS#330 Shigeyuki Muraki**  
Risk factors for multiple falls in a longitudinal population-based cohort study in Japan: The ROAD study

**ABS#331 Peter Pivonka**  
Computer simulation-based modeling of the pharmaceutical intervention of postmenopausal osteoporosis by denosumab

**ABS#332 Joanna Potts**  
Review of osteoporosis treatment at discharge and 12 months post-fracture at a regional hospital (Shoalhaven) 2008-2010

**ABS#333 Vladyslav Povoroznyuk**  
Effect of zoledronic acid in treatment of postmenopausal osteoporosis

**ABS#334 Timo Rantalainen**  
Marrow fat density predicts tibial bone geometry and strength in young athletic women

**ABS#335 Ramakrishnan Santosh**  
Screening for osteoporosis: An extended routine indication?

**ABS#336 Nailya Shamsutdinova**  
Estimation of risk factors and prevalence of the osteoporosis among the countrymen of the Republic of Tatarstan (Russia)

**ABS#337 Nailya Shamsutdinova**  
Prevalence of osteoporosis in Republic of Tatarstan (Russian Federation)

**ABS#338 K Singh**  
Osteoporosis among patients with coronary artery disease: An Indian scenario

**ABS#339 Attila Széplaki**  
Comparison of osteoporotic datas in active and non active elderly in our region

**ABS#340 John Walsh**  
Serum calcium as a predictor of cardiovascular disease in the Busselton Health Study

**ABS#341 Justin Cheng-Ta Yang**  
Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fracture: A systemic review

**ABS#342 Ming Zheng**  
Histopathology of femoral head: A retrospective review of 6161 cases

## CLINICAL METABOLIC BONE DISEASE

**ABS#343 Tuba Baykal**  
Bilateral transient osteoporosis of the hip during the last trimester of pregnancy

**ABS#344 Belinda Beck**  
A novel Australian calcium-specific diet questionnaire: Validity and reliability

**ABS#345 Julie Blair**  
Back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives: a prospective, multicentric, observational study

**ABS#346 Denise Brookes**  
Bridging the gap in the analysis of bone health in young individuals with cystic fibrosis

**ABS#347 Jemma Christie**  
Effect of levetiracetam and older antiepileptic drugs on bone health and body composition: A comparative randomised trial

## CLINICAL METABOLIC BONE DISEASE

**ABS#348 Catalin Cirstoiu**  
Possible effect of strontium ranelat in bone healing after hip fragility fracture

**ABS#349 Bharat Dave**  
Are there any risk factors in elderly, leading to hyponatremia following spine surgery & can it be prevented?

**ABS#350 Dinesh Kumar Dhanwal**  
Incidence of hip fracture in Rohtak, North India

**ABS#351 Olga Ershova**  
Hip fracture types in men and women 50 years and older

**ABS#352 Zdenek Fojtik**  
Prevention of osteonecrosis of the jaw during zoledronat use in the patients with multiple myeloma – experience from one centre

**ABS#353 Allison Heard**  
Low bone density in orthopaedic outpatient's fracture clinic

**ABS#354 Nathan Hewitt**  
25-hydroxyvitamin D levels, exercise capacity and vascular stiffness in patients on dialysis

**ABS#355 Irwin Kashani**  
Update in orthopaedic surgery: Reporting of minimal clinical important differences in surgical trials

**ABS#357 Leysan Myasoutova**  
Patients with inflammatory bowel diseases (IBD) are at risk of osteoporosis development

**ABS#358 Caryl Nowson**  
Food choices for calcium adequacy in older females

**ABS#359 Julie Pasco**  
What do GPs think and believe about osteoporosis? A cultural models approach to osteoporosis treatment and prevention

**ABS#360 Vladyslav Povoroznyuk**  
Effect of strontium ranelate on vertebral pain syndrome and functional abilities in postmenopausal women with systemic osteoporosis

**ABS#361 Yoshitomo Saita**  
Thirteen cases of atypical subtrochanteric and diaphyseal femoral fractures among the 2,238 cases of femoral fractures occurred during 2006 to 2010 in Japan

**ABS#362 Shahdab Samad**  
Bone mineral homeostasis including vitamin D levels and bone density in Indian HIV positive subjects

**ABS#363 Hulya Uzkeser**  
Serum IGF-1 levels in patients with acromegaly

**ABS#364 Hulya Uzkeser**  
Vitamin D levels in subjects with acromegaly

**ABS#365 Samuel vasikaran**  
External quality assessment of commercial assays for the reference standard bone turnover markers serum PINP and serum  $\beta$ CTX

## GENETICS IN BONE DISEASES

**ABS#366 Graeme Clark**  
Sequencing and genomewide association study in sporadic high bone mass cases

**ABS#367 Yide Miao**  
The association between polymorphisms in the osteoprotegerin gene and BMD in elderly men

**ABS#368 Yoshie Oishi**  
Relative risk factors for osteoporosis in young Japanese women between polymorphic variants of immune cytokine and bone mineral density

## GROWTH FACTORS AND CYTOKINES

**ABS#369 Shek Man Chim**  
EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase

**ABS#370 Damien Eeles**  
Anabolic stimuli enhance osteoblast IL-33 mRNA expression, and IL-33 enhances Wnt responses and osteoblastic mineralisation in vitro

**ABS#371 Nga Lam**  
Glypicans mediated regulation of bone morphogenetic protein signalling and osteogenesis in human cranial suture cells

**ABS#372 Youngkyun Lee**  
Novel extraneural role of Nogo-A: Modulation of osteoclastogenesis via positive feedback regulation of NFATc1

**ABS#373 Kirsty MacRae**  
Angiotensin II regulates RANKL:OPG ratio potentially through transactivation of ErbB receptors by EGF-like ligands

**ABS#374 Midori Nakamura**  
BMP-induced ectopic bone formation in c-Fos-deficient mice

**ABS#375 Suguru Omatsu**  
Interleukin-11 is required for the maintenance of axial bone mass in mice

**ABS#376 Christopher Vidal**  
Immune and osteogenic: The two faces of interferon gamma

**ABS#377 Andy Wu**  
MCP-1 gene expression dominates chemokine activation of skeletal repair and remodelling

## ORTHOPAEDICS

**ABS#378 David Doyle**  
Possible direct role of dopamine in healing of fractured bone

**ABS#379 Laura Gregory**  
Histomorphometric analysis suggests internal fixation stiffness does not alter the mode of fracture healing

**ABS#380 Yixin He**  
Higher CKIP-1 expression during impaired aged fracture healing

**ABS#381 Rhys Holyoak**  
Internal plate fixation induces a tissue response independent of fracture

**ABS#383 Nicolene Lottering**  
Evaluation of the Suchey-Brooks method for aging Australian Caucasian Populations using multislice computed tomography reconstructions of the pubic symphyseal surface

**ABS#384 Khadijeh Mirzaei**  
Probable association between angiopoietin-related growth factor and bone mineral density

**ABS#385 Khadijeh Mirzaei**  
VDR FokI polymorphism may modify effect of body mass index on bone mineral density in adult obese

**ABS#386 Khadijeh Mirzaei**  
Potential correlation between expression of the adipocyte-specific gene marker and bone mineral density

**ABS#387 Keita Nagira**  
Effects of minodronate on cortical bone response in rat to mechanical loading

**ABS#388 Mohammad Reza Oveisi**  
Glutathione reductase activity, smoking and menopause in relevance to bone loss

## OSTEOPOROSIS - CLINICAL MANAGEMENT

### Including Therapeutics

**ABS#389 Decio Armanini**  
Different effects of teriparatide and PTH 1-84 on bone and mineral metabolism in patients with severe osteoporosis

**ABS#390 Chung-Hwan Chen**  
Intraperitoneal injection of (-)-epigallocatechin-3-gallate (EGCG) increase bone volume in ovariectomized rats

**ABS#391 Wei-Hang Chua**  
Effect of a green tea extract on bone health and body composition in ovariectomised Sprague Dawley rats

## OSTEOPOROSIS - CLINICAL MANAGEMENT

### Including Therapeutics

**ABS#392 Monica Cirstoiu**  
Preventing bone loss in postmenopausal women with low bone mass and low-trauma forearm fractures

**ABS#393 Sandra Iuliano-Burns**  
Improving management of low trauma fractures in a tertiary hospital The "Fracture capture" project

**ABS#394 Yuji Kasukawa**  
Effects of bisphosphonate monotherapy or combined therapy with bisphosphonate and vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin in osteoporotic women

**ABS#395 Aishi Kimoto**  
Long-term intermittent minodronic acid (ONO-5920/YM529) treatment comparable to daily treatment in suppressing increased bone turnover while preventing reduction in bone mass and strength in ovariectomized rats with established osteopenia

**ABS#396 Hua Lin**  
Effect of a once-yearly zoledronic acid on BMD and the risk of falling in postmenopausal women with osteoporosis

**ABS#397 Heath McGowan**  
The effects of galnon on the osteoporotic rat Model

**ABS#398 F Ooi**  
Effects of combined jumping exercise and honey supplementation on tibia bone histomorphometry properties in young female rats

**ABS#399 Mika Palvanen**  
The Chaos Clinic— A randomized controlled trial of a falls clinic for prevention of falls and related fractures

**ABS#400 Markus Seibel**  
Cost-effectiveness of a targeted intervention to reduce the rate of refracture: Results of a 4-year prospective controlled study

**ABS#401 H Zeng**  
Intranasal salmon calcitonin for the treatment of osteoporotic bone pain after bilateral oophorectomy

## OSTEOPOROSIS EPIDEMIOLOGY, CLINICAL RISK FACTORS, AND CLINICAL ASSESSMENT

**ABS#402 T Baykal**  
Effect of long-term anticonvulsant therapy on bone mineral density and serum 25-hydroxyvitamin D level

**ABS#403 Jemma Christie**  
The relationship between smoking cessation, body fat and bone mineral density

## OSTEOPOROSIS EPIDEMIOLOGY, CLINICAL RISK FACTORS, AND CLINICAL ASSESSMENT

- ABS#404 Carolyn Coulson**  
Association between alcohol consumption and bone mineral density in a community-sample of elderly Australian men: Geelong Osteoporosis Study (GOS)
- ABS#405 Yi Dai**  
Relationship of postmenopausal circulating matrix metalloproteinase-3 and its inhibitor levels with bone mineral density and osteopontin level
- ABS#406 Fransiska Dewi**  
Assessment of dietary intake of calcium and magnesium by Singaporean Chinese
- ABS#407 Sham Dholakia**  
Are wrist fractures still a useful predictor of future hip fracture in 2011?
- ABS#408 Ameya Joshi**  
Study of bone mineral density and factors affecting same in type 1 diabetes mellitus
- ABS#409 Ratnesh Kanwar**  
Vitamin D status in healthy Indians aged 50 years and above
- ABS#410 Iolanthé Kruger**  
The effect of age on parathyroid hormone levels and bone turnover in black postmenopausal women
- ABS#412 Xiao-Ming Lin**  
Evaluation of milk basic protein supplementation on bone density and bone metabolism in Chinese young women
- ABS#413 Raman Marwaha**  
Thyroid function and bone mineral density among Indian subjects
- ABS#414 Khadijeh Mirzaei**  
Resting metabolic rate: Is a strong marker for BMD prediction in obese subjects?
- ABS#415 Tuan Nguyen**  
Independent validation of the Garvan nomograms for predicting absolute fracture risk: Tromso Study
- ABS#416 F Ooi**  
Bone turnover with combined aerobic dance exercise and honey supplementation in adult women
- ABS#417 Rekha Ramot**  
Risk factors for fragility hip fractures in elderly Asian Indians
- ABS#418 Rekha Ramot**  
Prevalence of vertebral fractures among elderly Asian Indians presenting with fragility hip fractures
- ABS#419 Naficeh Sadeghi**  
Relation of osteoporosis to catalase activity, smoking and menopause

- ABS#420 Mohammad Salamat**  
Comparison of bone mineral density, muscle strength and some hormonal and biochemical factors of blood serum in athletic (volleyball players) and non athletic girls
- ABS#421 Amanda Stuart**  
Medication usage four months post fracture - Results from AusICUROS
- ABS#422 Nikhil Tandon**  
Population prevalence of fragility fractures in India based on a nationwide questionnaire based epidemiological study
- ABS#423 Mika Yamauchi**  
Relationship between serum 25-hydroxyvitamin D levels and prevalent fracture risk in postmenopausal women
- ABS#424 Shuman Yang**  
Contributions of lean mass and fat mass to bone loss: The Dubbo Osteoporosis Epidemiology Study

## PAEDIATRIC BONE DISEASE AND BONE ACQUISITION

- ABS#425 Pascale Bridge**  
Longitudinal vBMD changes in peri-pubertal children
- ABS#426 Denise Brookes**  
Bone structural parameters in pre and pubertal individuals with cystic fibrosis (CF)
- ABS#427 Monita Gahlot**  
Effect of adiposity on bone mass in pre-pubertal obese children
- ABS#428 Alice Lee**  
Effects of maternal undernutrition and hypoxia during pregnancy on bone development of offspring
- ABS#429 Allison Poulton**  
Changes in bone mass and bone biomarkers in children with attention-deficit hyperactivity disorder receiving stimulant medication
- ABS#430 Tania Romano**  
Effects of age on the developmental timeline for the manifestation of the programmed bone deficits associated with fetal growth restriction
- ABS#431 Tania Romano**  
Effects of pregnancy and lactation on the bone of normal rat mothers and those exposed to uteroplacental insufficiency: a mechanism programming offspring bone health
- ABS#432 Benjamin Weeks**  
Bone benefits of an eight-month in-school jumping intervention are maintained after three years: POWER PE follow-up



# IOF-ECCEO12 | EUROPEAN CONGRESS ON OSTEOPOROSIS AND OSTEOARTHRITIS

MARCH 21-24, 2012, PALAIS DES CONGRÈS DE BORDEAUX - FRANCE



# IOF ECCEO12

BORDEAUX 2012

[WWW.IOF-ECCEO12.ORG](http://WWW.IOF-ECCEO12.ORG)













International Osteoporosis  
Foundation






## VENUE MAP



-  Public Restrooms
-  Disabled Restrooms
-  Plenary Hall
-  Gala Dinner
-  Exhibition & Poster Area
-  Lunches & Coffee Breaks
-  Registration Desk
-  Speaker Preview Room
-  Programme Session
-  Meet-the-Expert

# First Floor



As of July 8, 2011 • Subject to change • Not to scale